Modeling, optimization, and sensitivity analysis of a continuous multi-segment crystallizer for production of active pharmaceutical ingredients by Ridder, Bradley James
Purdue University
Purdue e-Pubs
Open Access Dissertations Theses and Dissertations
Winter 2015
Modeling, optimization, and sensitivity analysis of a
continuous multi-segment crystallizer for
production of active pharmaceutical ingredients
Bradley James Ridder
Purdue University
Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations
Part of the Chemical Engineering Commons, Mathematics Commons, and the Pharmacy and
Pharmaceutical Sciences Commons
This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.
Recommended Citation
Ridder, Bradley James, "Modeling, optimization, and sensitivity analysis of a continuous multi-segment crystallizer for production of





MODELING, OPTIMIZATION, AND SENSITIVITY ANALYSIS OF A 
CONTINUOUS MULTI-SEGMENT CRYSTALLIZER FOR PRODUCTION OF 
ACTIVE PHARMACEUTICAL INGREDIENTS 
A Dissertation 




Bradley J. Ridder 
In Partial Fulfillment of the 
Requirements for the Degree 
of 
Doctor of Philosophy 
May 2015  
Purdue University 




“We, the willing, led by the unknowing, are doing the impossible for the ungrateful. We 
have done so much, for so long, with so little, we are now qualified to do anything - with 




I first would like to thank my advisor, Dr. Zoltan Nagy, for his Job-like patience during 
my time here at Purdue. I recall fondly many chats in his office where he would give 
good advice on how to proceed with the project, while allaying my (many…!) fears and 
worries about school. I also would like to thank my group members David Acevedo, 
Yang Yang, and (again!) Andy Koswara. They were always willing to kick around ideas 
or consult about their findings in their own research. Furthermore, I extend great thanks 
to the former post-doc in our group, Dr. Aniruddha “Ani” Majumder now of the 
University of Aberdeen, Scotland. Ani offered a great deal of assistance with the 
implementation of the finite volume method, as well as answering my many conceptual 
questions. I would also like to thank my mother, who offered an immense amount of help 
and support during graduate school. 
iv 
 
TABLE OF CONTENTS 
Page 
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES ........................................................................................................... xi 
NOMENCLATURE ........................................................................................................ xvii 
ABSTRACT  ........................................................................................................... xxv 
CHAPTER 1. INTRODUCTION ................................................................................. 1 
1.1 Motivation ................................................................................................. 1 
1.2 Research Aim and Objectives.................................................................... 3 
1.3 Research Contributions ............................................................................. 5 
1.4 Thesis Structure ......................................................................................... 6 
CHAPTER 2. LITERATURE REVIEW ...................................................................... 9 
2.1 Introduction ............................................................................................... 9 
2.1.1 Synthesis……………………………………………………………9 
2.1.2 Separation ......................................................................................... 11 
2.1.3 Formulation ...................................................................................... 12 
2.1.4 Problems Related to Batch Processes in General ............................. 14 
2.1.5 Problems Related to Batch Crystallization ....................................... 15 
2.2 Overview of Technologies for Continuous Pharmaceutical Manufacturing ......... 20 
2.2.1 Quality-by-Design (QbD) Thinking ................................................. 21 
2.2.2 Critical Quality Attributes and Critical Process Parameters ............ 22 
2.2.3 The Problem of Quality-by-Testing ................................................. 23 
2.2.4 QbD and Crystallization ................................................................... 25 
2.2.5 Process Analytical Technology ........................................................ 25 
2.2.6 Real-Time Monitoring and Real-Time Release ............................... 30 




2.2.8 Technologies for Powders, Particles, and Tablets ............................ 32 
2.2.9 Pharmaceutical Informatics .............................................................. 35 
2.2.10 Process Control ................................................................................. 36 
2.2.11 Specific Examples of Plantwide Simulation, Control, and Optimization .....  
  .......................................................................................................... 37 
2.2.12 Uses of Simulation ........................................................................... 40 
2.3 The Basic Science of Crystallization ....................................................... 41 
2.3.1 Antisolvent Crystallization ............................................................... 45 
2.3.2 Cooling Crystallization ..................................................................... 46 
2.3.3 Other Methods .................................................................................. 46 
2.4 Kinetic Processes in Crystallization ........................................................ 48 
2.4.1 Nucleation ........................................................................................ 49 
2.4.2 Growth……………………………………………………………...52 
2.4.3 Dissolution ........................................................................................ 54 
2.4.4 Agglomeration and Breakage ........................................................... 55 
2.5 Polymorphic Form and Chiral Form ....................................................... 56 
2.5.1 General Background and Properties of Polymorphs ........................ 57 
2.5.2 Polymorph observation and control.................................................. 58 
2.5.3 Chiral Form ...................................................................................... 59 
2.6 The Quantitative Framework of Crystal Size Distributions .................... 60 
2.6.1 Crystal Size Distributions and General Mathematical Properties. ... 61 
2.6.2 Volume Size Distributions ............................................................... 63 
2.6.3 The Impact of Crystal Size Distribution and Crystal Properties ...... 63 
2.7 Population Balances ................................................................................ 64 
2.7.1 The Method of Moments (MOM) and Finite Volume Method ........ 68 
2.7.2 More Sophisticated Population Balance Modeling Approaches ...... 69 
2.7.3 Current Challenges in Continuous Crystallization and Population 
Balance Modeling ............................................................................. 70 




2.8.1 Basic Problem Formulation .............................................................. 73 
2.8.2 Pareto Optimality and the Pareto Frontier ........................................ 74 
2.8.3 Use of the Genetic Algorithm........................................................... 74 
CHAPTER 3. CURRENT LITERATURE ON CONTINUOUS 
CRYSTALLIZATION TECHNOLOGIES....................................................................... 76 
3.1 The MSMPR, MSMPR Cascade, and CoFlore™ Crystallizers .............. 76 
3.2 Plug-Flow Crystallizers ........................................................................... 77 
3.2.1 Multi-Segmented Plug-Flow Crystallizers ....................................... 79 
3.3 Other Types of Continuous Crystallizers ................................................ 80 
3.3.1 Continuous Microcrystallizers ......................................................... 82 
3.4 Table of Continuous Crystallization Technologies ................................. 83 
CHAPTER 4. MULTIOBJECTIVE OPTIMIZATION AND ROBUSTNESS 
ANALYSIS OF THE MULTI-SEGMENT, MULTI-ADDITION PLUG-FLOW 
ANTISOLVENT CRYSTALLIZER (MSMA-PFC) ........................................................ 88 
4.1 Abstract .................................................................................................... 88 
4.2 Introduction ............................................................................................. 89 
4.3 Methodology ............................................................................................ 91 
4.4 Model Diagram, and Governing Equations ............................................. 92 
4.4.1 Model Equations ............................................................................... 93 
4.4.2 Solution of Model Equations ............................................................ 97 
4.4.3 Multi-Objective Optimization Problem Formulation ..................... 101 
4.5 Results and Discussion .......................................................................... 103 
4.5.1 Nonconvexity of 43 and CV landscapes ...................................... 103 
4.5.2 Multi-Objective Optimization Results ........................................... 105 
4.5.3 Investigation Into the Sensitivity to Kinetic Parameters ................ 107 
4.5.4 Comparison between Heuristic Antisolvent Profiles and Rigorous 
Optimization ............................................................................................ 109 
4.5.5 Investigation of Design Robustness with Regards to Antisolvent Flowrate 
Error ........................................................................................................ 114 





CHAPTER 5. SIMULTANEOUS DESIGN AND CONTROL OF THE MSMA-PFC .  
  ........................................................................................................... 119 
5.1 Abstract .................................................................................................. 119 
5.2 Simultaneous Design and Control (SDC) Framework for the MSMA-PFC with 
Static Feed Flowrate and Static Total Antisolvent Flowrate ............................... 120 
5.3 Results for Simultaneous Design and Control (SDC) Optimization with Feed 
Flowrate and Antisolvent Flowrate Kept Static .................................................. 123 
5.3.1 Landscape Plots of Total Length vs. Number of Injections ........... 123 
5.3.2 Further Investigation of the Maximum Obtained L43 and Minimum 
Obtained CV ................................................................................... 124 
5.4 Problem Formulation for Case When Total Flowrates are Used as Decision 
Variables.............................................................................................................. 126 
5.5 Results and Discussion for Case When Antisolvent Flowrate and Feed Flowrate 
are Decision Variables ........................................................................................ 128 
5.5.1 Landscapes for Feed Flowrate ........................................................ 128 
5.5.2 Landscapes for Total Antisolvent Flowrate ................................... 129 
5.5.3 Landscapes for Residence Time ..................................................... 130 
5.5.4 Landscapes for Mass-Mean Crystal Size and Coefficient of Variation  
  ........................................................................................................ 131 
5.5.5 Number Fraction Distributions for the Case of 25 Injections ........ 133 
5.5.6 Antisolvent Profiles for the Case of 25 Injections.......................... 135 
5.5.7 Growth and Nucleation Profiles for the Case of 25-Injections ...... 136 
5.6 Summary and Conclusions .................................................................... 138 
CHAPTER 6. PARAMETRIC STUDY OF THE FEASIBILITY OF IN-SITU FINES 
DISSOLUTION IN THE MSMA-PFC ........................................................................... 139 
6.1 Abstract .................................................................................................. 139 
6.2 Introduction ........................................................................................... 139 
6.3 Prior Work on In-Situ Fines Removal ................................................... 140 
6.4 Parametric Study via Optimization of the Antisolvent Crystallizer ...... 142 
6.5 Model Framework ................................................................................. 143 




6.6.1 Boundary Conditions ...................................................................... 148 
6.6.2 Growth, Nucleation, and Dissolution Rate Laws ........................... 149 
6.6.3 Calculation of API Solubility ......................................................... 150 
6.7 Solution of Model Equations ................................................................. 151 
6.8 Optimization Problem Formulation ....................................................... 152 
6.8.1 Least-Squares Objective Function .................................................. 153 
6.8.2 List of Decision Variables and Bound Constraints ........................ 154 
6.8.3 Linear and Nonlinear Constraints ................................................... 156 
6.9 Solution of Least-Squares Problem by the Genetic Algorithm ............. 158 
6.10 Results and Discussion .......................................................................... 159 
6.10.1 Experimental Design Array ............................................................ 159 
6.10.2 Volume Fraction Distributions for Optimized Cases ..................... 162 
6.10.3 Main-Factor Analysis ..................................................................... 164 
6.10.4 No Dissolution is Used to Control Fines ........................................ 166 
6.11 Summary and Conclusions .................................................................... 168 
CHAPTER 7. SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS ..... 169 
7.1 Summary and Conclusions .................................................................... 169 
7.2 Future Directions ................................................................................... 173 
LITERATURE CITED ................................................................................................... 176 




LIST OF TABLES 
Table .............................................................................................................................. Page 
Table 1 Tradeoffs between batch and continuous crystallization. .................................... 17 
Table 2 Summary of pharmaceutical solids processing technologies. .............................. 34 
Table 3 The impact of crystallization on important drug properties, and the current 
capability of control. ......................................................................................................... 43 
Table 4 Table of continuous crystallization literature related to pharmaceuticals. ........... 84 
Table 5 Parameters for crystallization optimization from Alvarez and Myerson [169]. 
Copyright 2014 IEEE. ....................................................................................................... 97 
Table 6 Antisolvent flow profiles used to generate the crystal volume size distributions 
shown in Figure 4.6 and the corresponding performance index. .................................... 111 
Table 7 Flowrate Uncertainty Bounds For Robustness Analysis .................................... 114 
Table 8 Physical and chemical property data table used for modeling the antisolvent 
crystallization. ................................................................................................................. 150 
Table 9 Solubility data for biapenem-water-ethanol system. .......................................... 151 
Table 10 Decision variables and bound constraints for in-situ fines dissolution 
optimization. .................................................................................................................... 155 
Table 11 Linear and nonlinear constraints for in-situ fines dissolution optimization. .... 157 




Table .............................................................................................................................. Page 
Table 13 Experimental design table of factors and levels for the curve fit optimizations 
conducted. The numbers correspond to the level column in Table 12. The sum of the 
squares of the errors (SSE) and total amount of pure solvent added (Stotal) are given for 
each run. .......................................................................................................................... 161 




LIST OF FIGURES 
Figure ............................................................................................................................ Page 
Figure 2.1 Basic flowchart of a pharmaceutical manufacturing process. ......................... 11 
Figure 2.2 (a) Depiction of pharmaceutical lot testing. Blue samples are safe, but brown 
ones are off-specification. ................................................................................................. 24 
Figure 2.3 Venn diagram of critical process parameters of interest for measurement. As 
can be readily seen, the overwhelming majority of  sensors are invasive. ....................... 29 
Figure 2.4 Conceptual diagram of CPM implementing PAT for real-time release of final 
drug products. Information collected from analytical chemistry equipment (among other 
things) provides evidence of safety and quality. ............................................................... 35 
Figure 2.5 Antisolvent addition and cooling crystallization methods, and illustration of 
the solubility curve. The metastable zone is the supersaturation limit at which primary 
nucleation occurs. The black points are supersaturated solutions, and the gray points are 
undersaturated. .................................................................................................................. 44 
Figure 2.6 Basic kinetic phenomena in crystallization processes. .................................... 48 
Figure 2.7 (a) An irregularly shaped crystal has an infinite number of possible 
characteristic lengths one can arbitrarily choose for measuring its size. (b) The only shape 
possessing a unique direction is a perfectly spherical crystal, for which all of the possible 
characteristic lengths (passing through the sphere’s center) are exactly the same. .......... 61 
Figure 2.8 Crystal size distribution and the attendant cumulative summation. ................ 61
xii 
 
Figure ............................................................................................................................ Page  
Figure 2.9 Depiction of equal mass closures for two different populations of particles... 66 
Figure 4.1 Model of segmented plug flow crystallizer system. ........................................ 92 
Figure 4.2 L43 and  response surfaces for two injections. The landscapes (a) and (b) 
present nonconvexity that makes gradient optimization difficult. Great sensitivity to 
antisolvent flowrate is observed. The contour plots (c) and (d) are zoomed closer to the 
extrema for clarity. .......................................................................................................... 104 
Figure 4.3 Pareto frontier plots for four injections (  vs. L43) and different sets of 
kinetic rate parameters, kb and kg. The ’s in the legend correspond to multipliers of the 
base case, e.g. γb = kb’/ kb. The base case corresponds to γb = 1 and γg = 1, with kb = 1.3 x 
10
8 #/(m3·s), and kg = 9.9 x 10
-7 m/s. We observe that there is some sensitivity with 
respect to these parameters on the Pareto frontier, but mainly the effect appears in L43. 
Little shift is seen in the realized coefficients of variation. For clarity, only the final 25 
generations of each parameter set are plotted. The black arrow (L43 = 89.98 µm,  =
0.20) is a representative point that is referred to in Figure 4.4, Figure 4.5, and Figure 4.6.
 ......................................................................................................................................... 107 
Figure 4.4: Variation in L43 and CV for the representative chosen point. Significant 
sensitivity is observed with respect to kg. Copyright 2014 IEEE. ................................... 108 
Figure 4.5: Volume size distributions of crystals as a function of nucleation rate constant, 
kb. It is observed that increasing kb decreases the mean size (approximately the mode), but 
shape-wise the peaks are isomorphic. The second mode in the blue curve is eliminated 




Figure ............................................................................................................................ Page 
Figure 4.6: Volume fraction distributions of crystals for 1, 2, 3, and 4 equal-flow 
injections, and the optimal 4-injection profile of the antisolvent. In the 1, 2, 3, and 4 
injection plots, 200 ml/min of antisolvent is split equally a corresponding number of ways 
among the injections. The optimal result uses the flows taken from the representative 
point (Figure 4.2, black arrow)........................................................................................ 110 
Figure 4.7 Concentration vs. external length plot for equal splits of total antisolvent 
across one, two, three, or four sections. The optimal result from the representative point is 
the "Optimal" line. Dotted lines are the concentration in the crystallizer. Solid lines are 
solubility concentrations. ................................................................................................ 113 
Figure 4.8 Robustness analyses with respect to flowrate by varying a single flowrate. The 
Roman numerals correspond to the particular MSMA-PFC segment for which random 
antisolvent flows are being sampled by the simulation. The red dot is the result for the 
nominal (zero-error) case. Copyright 2014 IEEE. .......................................................... 116 
Figure 4.9 Robustness analyses for multiple varying flowrates. The Roman numerals 
refer to which stage, and all others preceding it, are being sampled by the simulation. The 
red dot is the result for the nominal (zero-error) case. Copyright 2014 IEEE. ............... 117 
Figure 5.1 Flowchart for the simultaneous design and control (SDC) optimization of the 
MSMA-PFC array. The algorithm proceeds by cutting a PFC array of a given total length 
into progressively smaller subunits. Genetic algorithm optimization is performed on each 





Figure ............................................................................................................................ Page 
Figure 5.2: Results of the simultaneous design and control (SDC) optimization 
framework for the MSMA-PFC array over length, number of injections, and antisolvent 
profile, showing (a) the L43 crystal size, (b) coefficient of variation (CV), and (c) the solid 
crystal yield computed via equation (5.1). ...................................................................... 124 
Figure 5.3: Results for SDC over total length, number of injections, and antisolvent 
profile. We have chosen two points from the surfaces in Figure 5.2 for examination – one 
point corresponding to the maximum obtained L43, and the other corresponding to the 
minimum obtained . (a) shows the volume CSD’s for these two points. The antisolvent 
profiles that produced these distributions are shown in (b). ........................................... 126 
Figure 5.4 Optimized landscapes of feed volumetric flowrates (Vfeed) against total length 
of PFC array and number of PFC injections. In (a) the objective was to maximize L43. In 
(b) the objective was to minimize . ............................................................................ 128 
Figure 5.5 Optimized landscapes of total antisolvent volumetric flowrates (Atotal) against 
total length of PFC array and number of PFC injections. In (a) the objective was to 
maximize L43. In (b) the objective was to minimize . ................................................ 129 
Figure 5.6 Optimized landscapes of residence time () against total length of PFC array 
and number of PFC injections. In (a) the objective was to maximize L43. In (b) the 
objective was to minimize . ........................................................................................ 130 
Figure 5.7 Optimized landscapes of mass-mean crystal size (L43) against total length of 
PFC array and number of PFC injections. In (a) the objective was to maximize L43. In (b) 




Figure ............................................................................................................................ Page 
Figure 5.8 Optimized landscapes of coefficient of variation () against total length of 
PFC array and number of PFC injections. In (a) the objective was to maximize L43. In (b) 
the objective was to minimize . .................................................................................. 133 
Figure 5.9 Number fraction distributions for the case of 25 injections. Each plot 
corresponds to a different total length. (a) 1 meter and (b) 50 meters. ........................... 134 
Figure 5.10 Antisolvent fraction profiles for the case of 25 injections. Each plot 
corresponds to a different total length. (a) 1 meter, (b) 50 meters. ................................. 135 
Figure 5.11 Growth and nucleation rate profiles for the case of maximizing mass-mean 
crystal size. (a) 1 m total length, (b) 50 m total length. .................................................. 136 
Figure 5.12 Growth and nucleation rate profiles for the case of minimizing coefficient of 
variation. (a) 1 m total length, (b) 50 m total length. Note the change of x-scale in (b). 137 
Figure 6.1 Information flow diagrams in a multisegment crystallizer for (a) cooling 
crystallization and (b) antisolvent crystallization............................................................ 142 
Figure 6.2 Diagram of the MSMA-PFC. Seeded liquid solvent, with solute concentration 
C0 flows in from the left into a mixing chamber (gray box). The dilution correction factor, 
γj, is applied to the exit stream around each mixing point (red dashed boxes). The 
combined streams then flow into a plug-flow segment (blue rectangle). Antisolvent 
reduces solubility, triggering nucleation and growth. Streams of pure solvent are utilized 
to push the solution below solubility when necessary. ................................................... 143 
Figure 6.3 Mass balance envelopes that are used to derive γ dilution correction factor. 
Incoming streams are positive; outgoing are negative. ................................................... 146 
Figure 6.4 Volume-fraction distribution for run #1. ....................................................... 162 
xvi 
 
Figure ............................................................................................................................ Page 
Figure 6.5 Volume-fraction distribution for run #11, a nucleation-dominated case. ...... 163 
Figure 6.6 Optimal fit predicted by analysis of the orthogonal array design. ................. 165 
Figure 6.7 Supersaturation profile for project optimum, representative of the other 





List of Mathematical Symbols 
Symbol Definition Units 
 Refers to ℎ crystallizer segment - 
 Solubility curve fitting parameter mg/m3 
 Solubility curve fitting parameter - 
 Total antisolvent allotment ml/min 
  Nucleation rate law #/m3∙s or #/kg∙s 
 Initial concentration mg/m3 or kg/kg 
 Saturation (solubility) concentration mg/m3 or kg/kg 
1, 2, 3 Characteristic lengths µm 
 Mass-mean crystal size µm 
 Total number of crystals per unit volume #/m3 
 Three-space; 3D Cartesian coordinates - 
 ! Flowrate of pure solvent into segment  ml/min 
 "# Relative solubility - 
  Total pure solvent allotment ml/min 
$%#&'( Decomposition point of API K 
xviii 
 
$"##)# Freezing point of solution K 
*+% Antisolvent volume fraction percentage % 
*- Water mass fraction - 
.! Antisolvent apportionment into segment  - 
/00#" Inner diameter of crystallizer mm 
1(3) Objective function - 
1∗(3) Optimal value of objective function - 
16,"7# Target volume fraction distribution 1/m 
16 Volume fraction distribution 1/m 
89 Nucleation law rate constant #/m3∙s 
8% Dissolution law rate constant m/s 
87 Growth law rate constant m/s 
86 Shape factor - 
: Initial (seed) crystal size distribution #/m4 
:; Volume-based crystal size distribution m3/m4 
:!  Crystal size distribution in segment   #/m4 
<! Pure solvent apportionment into segment  - 
=> , =? , =) Velocities in the Cartesian directions m/s 
@+A Antisolvent mass fraction - 
@ Total length of crystallizer m 
3BC Lower bound on 3  - 
xix 
 
3DC Upper bound on 3  - 
E#> Gradient over the external coordinates - 
E0 Gradient over the internal coordinates - 
9 , 7 Multipliers of base-case nucleation and growth 
constants in section 4.5.2 
- 
! Dissolution correction in segment  - 
F##% Mean size of seed distribution µm 
GH, Mean size of number distribution in figure 
Figure 2.8 
µm 
G, Third moment of seed distribution - 
GI 8J moment depends on 8 
K& Density of solid crystalline API kg/m3 
L##% Standard deviation of seed distribution µm 
∆ Absolute supersaturation mg/m3 
Ψ Energy, mass, momentum, or population - 
 Birth rate of new particles #/m4∙s 
 Concentration of API mg/m3 or kg/kg 
 Coefficient of variation - 
O Death rate of particles #/m4∙s 
O Dissolution rate m/s 
P Growth rate m/s 
Q Number of crystal size bins - 
xx 
 
 Internal characteristic length coordinate µm 
 Total number MSMA-PFC segments - 
  Supersaturation ratio - 
$ Temperature K 
R Yield - 
S Nucleation order - 
/ Dissolution order - 
1 Number fraction distribution 1/m 
T Growth order - 
: Number density (crystal size distribution) #/m4 
U Parameter in equation  - 
< Standard deviation of CSD in figure Figure 2.8 µm 
 Time s 
= Antisolvent apportionment decision variable in 
section 4.4.3 
- 
@, V, W Cartesian directions m 
X Vector of antisolvent flowrates ml/min 
Y Multiobjective criteria vector - 
Z Vector of growth rates m/s 
[ Vector of decision variables - 
\(3) Vector of inequality constraints - 
](3) Vector of equality constraints - 
xxi 
 
3 State vector - 
, ^ Parameters in equation (2.7)  
_ Seed mass loading percentage % 
 Residence time s 





















List of Acronyms 
Acronym Definition 
%RH Percent relative humidity 
API Active pharmaceutical ingredient 
ATR FT-IR Attenuated total reflectance Fourier 
transform infrared spectroscopy 
CFD Computational fluid dynamics 
COBC Continuous oscillatory baffled crystallizer 
CPM Continuous pharmaceutical manufacturing 
CPP Critical process parameter 
CQA Critical quality attribute 
CSD Crystal size distribution 
CSTR Continuous stirred tank reactor 
CT Couette-Taylor 
DEM Discrete element method 
DOE Design-of-experiments 
DSC Differential scanning calorimetry 
FBRM Focused beam reflectance measurement 
FDA Food and Drug Administration 
FDF Final dosage form 
FEM Finite element method 
FV Finite volume 
xxiii 
 
GA Genetic algorithm 
IR Infra-red 
MILP Mixed-integer linear program 
MINLP Mixed-integer nonlinear program 
MIS Management information systems 
MOCH Method of characteristics 
MOM Method of moments 
MOO Multiobjective optimization 
MSMA-PFC Multi-segment, multi-addition, plug flow 
crystallizer 
MSMPR Mixed suspension, mixed product removal 
crystallizer 
NSGA-II Nondominated sorting genetic algorithm 
PAT Process analytical technology 
PBE Population balance equation 
PBM Population balance modeling 
PCA Principal component analysis 
PFC Plug flow crystallizer 
PLS Partial least squares 
PVM Particle vision monitoring 





RTR Real time release 
SDC Simultaneous design and control 
SQP Sequential quadratic programming 
SSE Sum of the squared errors 
WENO Weighted essentially non-oscillatory 
method 






Ridder, Bradley J. Ph.D., Purdue University, May 2015.  Modeling, Optimization, and 
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We have investigated the simulation-based, steady-state optimization of a new type of 
crystallizer for the production of pharmaceuticals. The multi-segment, multi-addition 
plug-flow crystallizer (MSMA-PFC) offers better control over supersaturation in one 
dimension compared to a batch or stirred-tank crystallizer. Through use of a population 
balance framework, we have written the governing model equations of population 
balance and mass balance on the crystallizer segments. The solution of these equations 
was accomplished through either the method of moments or the finite volume method. 
The goal was to optimize the performance of the crystallizer with respect to certain 
quantities, such as maximizing the mean crystal size, minimizing the coefficient of 
variation, or minimizing the sum of the squared errors when attempting to hit a target 
distribution. Such optimizations are all highly nonconvex, necessitating the use of the 
genetic algorithm. Our results for the optimization of a process for crystallizing 
flufenamic acid showed improvement in crystal size over prior literature results. Through 
the use of a novel simultaneous design and control (SDC) methodology, we have further 
optimized the flowrates and crystallizer geometry in tandem. 
xxvi 
 
 We have further investigated the robustness of this process and observe significant 
sensitivity to error in antisolvent flowrate, as well as the kinetic parameters of 
crystallization. We have lastly performed a parametric study on the use of the MSMA-
PFC for in-situ dissolution of fine crystals back into solution. Fine crystals are a known 
processing difficulty in drug manufacture, thus motivating the development of a process 
that can eliminate them efficiently. Prior results for cooling crystallization indicated this 
to be possible. However, our results show little to no dissolution is used after optimizing 
the crystallizer, indicating the negative impact of adding pure solvent to the process 
(reduced concentration via dilution, and decreased residence time) outweighs the positive 
benefits of dissolving fines. The prior results for cooling crystallization did not possess 
this coupling between flowrate, residence time, and concentration, thus making fines 
dissolution significantly more beneficial for that process. We conclude that the success 
observed in hitting the target distribution has more to do with using multiple segments 
and having finer control over supersaturation than with the ability to go below solubility. 
Our results showed that excessive nucleation still overwhelms the MSMA-PFC for in-situ 
fines dissolution when nucleation is too high. 
1 
 
CHAPTER 1. INTRODUCTION 
1.1 Motivation 
In recent years, the continuous production of pharmaceuticals has grown considerably in 
research attention. Currently, most pharmaceuticals are produced via batch processes, at 
considerable expense and difficulty. A variety of financial [1]–[11] and regulatory [12] 
pressures on the pharmaceutical industry has motivated the research into cost-saving, 
streamlined approaches to their operations. The “blockbuster drug” business model has 
proven financially unsustainable. Drugs can take from 10-15 years to develop, have only 
a 20% chance of FDA approval, and cost between $800 million and $1 billion to bring to 
market [13]–[15]. Many currently-available, on-patent drugs lack suitable profit-
generating replacements once their predecessors go off-patent, and the drug industry 
faces stiff competition from generic manufacturers. 
 
Crystallization is an area of considerable interest from the standpoints of continuous drug 
manufactures as well as process systems engineering. While useful for small quantities of 
drugs, drugs which require higher production volumes would benefit greatly from 
continuous crystallization. As a pure systems problem, crystallization processes are 
interesting due to their high nonlinearity. 
2 
 
These processes demand a different set of mathematical tools to model and optimize 
them properly, as well as different solution approaches. 
  
Continuous crystallization systems, while already heavily used in many other industries, 
have attracted new interest for application to pharmaceuticals. Current methods of 
crystallization are focused overwhelmingly on batch systems. This is problematic, since 
batch systems have intrinsic drawbacks related to design, control, and scale-up. 
Continuous crystallization systems can be considered a sub-field of the more general 
research field of process intensification. 
 
A variety of new crystallizer designs have been proposed that can, via novel flow 
chemistry, crystallize drugs with a greater level of precision and control. One particular 
type of continuous crystallization is the plug flow crystallizer (PFC), which has been the 
subject of several investigations in recent literature (see Table 4 beginning on page 84). 
Lakerveld et al. [16] pointed out the need for more investigation into the crystallizer 
design itself, and that detailed modeling would be needed for the optimization thereof. A 
new design based on the PFC is the multisegment, multi-addition plug flow crystallizer 
(MSMA-PFC). This crystallizer is a group of PFCs linked in series, with an independent 
supersaturation actuator for each segment. This design allows for greater control of 
supersaturation in one dimension versus a stirred tank. 
 
Currently, there is a lack of design and optimization methodology in the literature for 
continuous crystallization systems. Multiobjective optimization is a useful tool for fully 
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investigating the tradeoffs between possible designs of a system, as well as identifying 
the envelope of attainability [17]. Much benefit could be achieved by use of an integrated 
framework for the design, optimization, and robustness analysis of new crystallizer 
designs, of which the MSMA-PFC is a contemporary example. Such a methodology 
would help trim the design space considerably when searching for an optimal design. 
 
The robustness and sensitivity of continuous crystallization systems for pharmaceutical 
use has also gone unstudied. The topic of sensitivity in crystallizers has been examined 
for the case of batch crystallizers by Ma et al. [18] using a worst-case framework, which 
among other conclusions showed that inaccurate control can wipe out the entire benefit of 
optimal control. For effective design and operation of new crystallizer technologies, it is 
important to know the impact of parametric uncertainty, random disturbances, control 




1.2 Research Aim and Objectives 
The aim of this research is to develop a framework for modelling and optimizing a new 
type of antisolvent plug-flow crystallization systems, the MSMA-PFC. To analyze 
continuous crystallization system, we borrow the concepts of constrained optimization 
from the field of process systems engineering. By use of this modelling and optimization 
framework, we can investigate the capabilities of the system for achieving desirable 
properties of the generated crystals. Such a framework can gauge the feasibility of a plug-
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flow crystallization system for producing high-quality crystals of a particular drug, given 
correct experimental parameters. It can also predict correct operating conditions and 
vessel designs that will produce crystals with desired properties. We summarize our aims 
as: 
a. To gain a broad view of the impact of continuous crystallization’s potential via a 
thorough literature review of the continuous drug manufacturing research field. 
b. To develop a model-based simulation framework for modelling the plug-flow 
crystallization process. 
c. Unite the simulation framework with a multiobjective optimization methodology 
in order to investigate possible control strategies. This combined simulation-
optimization based framework is used throughout this work as a method of 
optimizing the properties of crystals at the exit of the crystallizer. 
d. As an example of this framework in action, analyze the performance of a new 
type of plug-flow crystallizer, termed the multi-segment, multi-addition plug-flow 
crystallizer (MSMA-PFC). This apparatus consists of a group of PFC’s linked in 
parallel, each with independent supersaturation control. To demonstrate this 
framework in action, our chosen crystal properties have been the size and spread 
of the crystal size distribution – though the framework is extendable to other 
important quality measures such as polymorph content or aspect ratio. 
e. Examine the sensitivity of the crystallization process, and determine the how this 
sensitivity affects the design considerations for design and control. 
f. To create a simultaneous design and control methodology which optimizes over 
not only flowrates but the actual crystallizer geometry as well. 
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g. To investigate the feasibility of plug-flow antisolvent crystallization for 
eliminating undesirable small crystals (“fines”). 
1.3 Research Contributions 
The main contributions of this thesis are summarized as: 
a. This thesis surveys not only the continuous crystallization literature, but the 
continuous pharmaceutical manufacturing field holistically. By overviewing the 
research field in this manner, it becomes more apparent how our contributions fit 
into the greater network of ideas and concepts. 
b. Through use of a population balance model-based framework, we have developed 
a model for the MSMA-PFC, coupled with the mass balance equation, which can 
track the properties of drug crystals at the exit of the crystallizer. This model 
incorporates the effects of dilution and also dissolution. 
c. Demonstrated that the optimization of a multi-segment plug-flow crystallizer is a 
nonconvex problem. 
d. Used multi-objective optimization (aided by the genetic algorithm) to investigate 
the envelope of performance of the crystallizer, and compared obtained values 
with prior literature results. Our results compare favorably (e.g. larger crystals). 
This methodology was able to successfully surmount the observed nonconvexity 
of the MSMA-PFC optimization problem. 
e. Investigated the sensitivity and robustness of the MSMA-PFC with respect to 
uncertainty in important values such as flowrate and kinetic rate parameters. 
Using a Monte-Carlo method, we determined that error in flowrate significantly 
affects the performance of the MSMA-PFC. Also, we found that significant 
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coupling exists between errors in crystallizer inputs, which significantly impacts 
the design and operation of the crystallizer. 
f. Through use of a simultaneous design and control (SDC) methodology, we 
successfully optimized not only the individual flowrates in the MSMA-PFC, but 
the geometry of the crystallizer as well. Significant improvement is shown when 
using SDC versus optimizing flowrates alone on a static geometry. 
g. Demonstrated that the dissolution of fine crystals in-situ is a sub-optimal strategy 




1.4 Thesis Structure 
CHAPTER 1 of this thesis gives a broad overview of the remainder of the work. This is 
to supply the reader with a “bird’s eye view” of the topics discussed herein.  
 
CHAPTER 2 provides the reader with a literature review. We begin with a discussion of 
the current manufacturing process in pharmaceuticals, and discuss various problems and 
challenges related to it. New continuous technologies are discussed as well in areas 
outside of crystallization. We move then onto the importance of crystallization in the 
manufacture of drugs, and how continuous crystallization can solve many current 
problems encountered with batch crystallization. The remainder of the chapter is 




CHAPTER 3 provides a more specific literature review on the topic of continuous 
crystallization. We give an overview of many contemporary devices for crystallization. A 
table at the end of the chapter neatly summarizes many studies of continuous 
crystallization for the reader. 
 
CHAPTER 4 is the first contribution chapter of this work. It presents our results on the 
multiobjective optimization of the MSMA-PFC. We further investigate the robustness of 
the design with respect to uncertainty in kinetic parameters as well as flowrate. 
 
CHAPTER 5 revisits the system from CHAPTER 4 on the simultaneous design and 
control (SDC) problem.  In this problem, we optimize the crystallizer not only over the 
flow profile, but the vessel geometry as well. Significantly more control over mean size is 
shown possible by optimizing both design and control in tandem. 
 
CHAPTER 6 is the final contribution of this work. In this chapter, we have investigated 
the use of the MSMA-PFC for in-situ dissolution of fine crystals. Unlike in Chapter 4, the 
new MSMA-PFC is capable of going below solubility, thus dissolving fine crystals while 
keeping large ones. The results show however, that dissolution is shown to be a sub-
optimal strategy. Comparison with prior in-situ fines dissolution work is given as well. 
 
CHAPTER 7 is our summary and future directions chapter. In this chapter, we 
summarize the results of the previous chapters. We furthermore expound upon new 
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technologies and extensions of this work that can be of significant impact in 




CHAPTER 2. LITERATURE REVIEW 
2.1 Introduction 
We begin with a general overview of the present state of pharmaceutical manufacturing, 
which foreshadows the benefits of continuous pharmaceutical manufacturing (CPM) 
discussed in section 2.2. The flowchart in Figure 2.1 below gives an overview of a drug 
manufacturing process (based on the diagrams in [1], [19]). This flowchart will serve as a 
useful guide in the discussion of pharmaceutical manufacturing. Once the basic process 
overview behind pharmaceutical manufacturing is presented to the reader, it will be clear 






In Figure 2.1 below, raw materials enter the process at two points. At the start of the 
process, raw material precursors are transported to the manufacturing site for use in 
synthesis to create that active pharmaceutical ingredient (API). The API is the molecule 
which actually provides the curative effect to the patient. 
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During this phase of the operation, precursors are reacted together, which usually takes 
several reactions and work-up steps to attain the desired molecular form. In certain 
instances (e.g. penicillin), a bioreactor or fermenter is used to directly synthesize the API, 
followed by a variety of cleaning and filtration steps. Multiple syntheses reduce overall 
yield significantly. During this phase, workers may be in contact with toxic amounts of 
precursor or final API compounds. The solution containing the API is contaminated with 









Observing the middle of Figure 2.1, crystallization is the secondary process in 










Manufacturing StageProblems and Challenges Equipment
●  Feedstock variability
●  Sterility
●  May be a particle phase
●  May be biological
●  Incomplete reaction
●  Safety issues
●  Organic solvents and pollution
●  Batch-to-batch variability
●  Control and scale-up difficulties in batch 
mode.
●  Observation is difficult.
●  Batch-to-batch variability.
●Wide uncertainty in experimental kinetic 
parameters
●  Difficult to observe process.
●  Batch crystallization
●  Stirred batch reactor
●  Fermenter or bioreactor
●  Wet granulator
●Dry granulator/roller compactor
●  Powder blenders
●  Hot extrusion
●Mathematically complicated to model.
●Complicated fluid-solid interactions
●  Difficult to handle powder phases.
●  Difficult to observe process.
●Results from prior processes can affect 
hardness, dissolution rate, color, taste, 
friability, etc.
●Difficult to achieve uniform thicknesses for 
coated tablets.











investigating a new type of crystallizer. This new MSMA-PFC design is an intensified 
process that alleviates many of the problems described in the crystallization section of 
Figure 2.1. Crystallization is a key pre-formulation operation in pharmaceuticals [1], [5], 
[20]–[23], and between 80% and 90% of drugs are purified in this way [21], [22], [24]. 
Crystallization is predominant because it can achieve very high purities (> 98%). 
Crystallization also does not require harsh conditions (e.g. distillation), which would 
likely destroy most API molecules. Multiple crystallizations may be necessary to achieve 
sufficient purity, much in the same way that multiple equilibrium stages are required for 
distillation, liquid-liquid extraction, and gas-liquid extraction. Following crystallization, 
crystals require filtration, washing, and drying. The performance of the filtration, 
washing, and drying processes are highly dependent on the properties of the product 






“Formulation” is meant the final steps required to convert refined pharmaceutical crystals 
and various excipients into a “final dosage form” (FDF). As the name implies, an FDF is 
meant to deliver a precisely metered quantity of API to the patient.  Besides the quantity 
of drug, the dosage form must possess the desired physical and pharmacological 
properties that ensure proper bioavailability in the human body. The complexity of the 
human body places tight constraints on the properties of the FDF [25]. FDF’s can take on 
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many forms, which can dramatically change the formulation process. Examples are too 
numerous to list exhaustively, but include oral tablets (hard tablets, lozenges, chewable 
tablets for children, sublingual tablets), injectable drugs, topical creams, and inhalants. 
Each of these FDF’s has a variety of engineering challenges associated with continuous 
manufacturing. Since crystallization often cannot produce crystals with the desired 
properties, a variety of particle modification processes are used to remedy this during 
formulation. These include agglomeration operations such as wet granulation, roller-
compaction, and hot-melt extrusion [26]–[29]. Subsequently, API crystals are blended 
with a variety of excipients to attain desired properties (e.g. dissolution rate, color, 
sweetness, etc.). Excipients may also be process control agents, such lubricants, which 
can enhance qualities such as flowability [29]. Excipients often compose the majority of 
the dosage form [30].  Blending of powders together is another challenging process, since 
it is difficult to mix powders with consistent homogeneity. Following blending is 
typically a granulation process, which turns fine powders into larger chunks. Granulation 
is done for a variety of reasons, such as making the powder phase easier to handle, make 
tablets easier to press [25], and reducing the respiratory and explosion hazards from dust 
clouds [19]. Increasing the level of control over the CSD would simplify much of the 
formulation stage. Once powders are sufficiently mixed and/or granulated, they are 
pressed under mechanical force to create tablets. The thesis by Cipich on gives a good 
overview of several processes involved in continuous tablet production, including 





To summarize the pharmaceutical manufacturing process, the operations commonly 
found in the pharmaceutical industry are complicated from a scientific and engineering 
standpoint. Most operations after the synthesis stage possess at least two phases, such as 
crystallization slurries or wet granulation mixes. Analysis, design, scale-up, observation, 
and control of these processes is difficult to do. This is further complicated by the batch 
nature common to most of these processes, which are not only spatially complex, but 
time-dependent as well. Few major improvements to these processes have been attempted. 
Our objective in this work is, through the use of a rigorous modeling and optimization 





2.1.4 Problems Related to Batch Processes in General 
Most pharmaceutical manufacturing operations, such as crystallization, are performed 
using inefficient batch processes, and basic understanding of these important unit 
operations is limited.  This is in contrast to the bulk chemicals, food, and semiconductor 
industries which are mostly run continuously in well-understood processes [9], [31]. 
Manufacturing costs accounts for about 30% of sales for brand-name drug manufacturers 
[11], with 30-40% as the general industry average [7], [11]. In addition to being labor-
intensive and environmentally wasteful, current drug manufacture is error-prone [32], 
leading to costly recalls and contamination [7], [9], [15], [19]. The drug industry’s batch 
operations are also widely distributed geographically, which requires costly, time-
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consuming transport of material between manufacturing plants [33]. Clearly, complete 
manufacturing within a single manufacturing site would be preferable to playing “factory 
pinball” with various drug components.  
 
Despite being worth over $250 billion [8], the pharmaceutical industry’s manufacturing 
apparatus has become antiquated. Most industries shift to continuous production as 
quickly as affordable [13]. This is because, at large economies-of-scale, continuous mode 
is more efficient than batch processes. The reader might wonder, “Why the lag in 
technology?” The reason for this lag, is that the pharmaceutical industry has historically 
been tightly regulated, with even minor changes to processes requiring re-approval [13], 
[34]. However, recent reforms [12], [35], [36] to the regulatory framework have greatly 
lessened this impediment and given much more freedom to make process changes within 
an approved “design space” (see [34]). To address this lag in technology, the 
pharmaceutical industry has recently expressed great interest in upgrading and 




2.1.5 Problems Related to Batch Crystallization 
We are especially interested in this work on problems related to batch crystallization, and 
how continuous crystallization can solve many of these problems. The continuous 
crystallization of pharmaceuticals is a research endeavor with very high potential impact, 
as crystallization is a ubiquitous process operation in pharmaceuticals and a key stage at 
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which quality can be engineered into the final product. This folds in with the concept of 
“QbD”, discussed in section 2.2.1. Most industrial pharmaceutical crystallization is done 
batch-wise, which has a variety of drawbacks related to scale-up, observation, and control. 
Efficient, controlled production of drug crystals with desired properties has been 
described as a “primary bottleneck” to large-scale production of certain drugs [37]. 
Improving crystallization operations can improve the manufacturing process as a whole, 
since the properties of the produced crystals affect the performance of subsequent 
processes [21], [38]. Table 1 below summarizes the problems associated with batch 
crystallization. Plumb [19] neatly summarizes the problems associated with batch 
manufacturing as follows: “Batch processes are poorly understood, time-dependent, and 
scale-dependent operations.” This is in contrast to continuous processes, which are 
capable of attaining a physically and mathematically well-defined steady-state of 
dynamic equilibrium. Batch processes also fail to process all material in a uniform, 
consistent fashion, due to the existence of uncontrollable spatial gradients in fluid 
velocity, supersaturation, temperature, solids fraction, and chemical composition. This is 
in contrast to a steady-state, continuous flow process, over which significant control over 












































































































































































































































































































































































































































































































































































































































































































































































































Scale-up is another serious problem encountered in batch crystallization. In chemical 
engineering, a common problem is taking a small, laboratory-scale system, and 
increasing its production capacity to meet mass-market demand. For drugs, API 
crystallization is almost entirely done batch-wise, and direct scale-up from the laboratory 
model is difficult to achieve [39]. The main reason the scale-up of agitated crystallization 
vessels is difficult is due to incongruous scaling rules for heat, mass, and momentum 
transfer. To scale-up a crystallizer, one calculates a set of dimensionless numbers based 
upon the geometry of the crystallizer, the impeller design, fluid properties, and the power 
input to the impeller. Dimensional analysis of the governing equations shows that it is 
impossible to preserve all dimensionless groups with increasing tank size, regardless of 
agitation speed [39], [40]. The phenomena described by these dimensionless numbers – 
such as heat transfer rate, hydrodynamic flow patterns, shear rate, and suspension 
velocity - scale in opposing ways [40], [41]. Plumb [19] provides numerical results 
clearly indicating this problem, and Mersmann and Foster [42] gives a large table of 
dimensionless correlations for stirred vessels. Significant changes in the velocity field can 
result upon scale-up, resulting in supersaturation gradients and ultimately a CSD that 
does not meet desired characteristics [40], [43]. Scale-up also leads to changes in the 
internal hydrodynamics of the crystallizer that are difficult to model and predict [39], [44]. 
These issues are discussed at length by Genck [39], Wei [45], and in the text by Peker 
and Helvaci [46]. In continuous crystallization (and CPM in general), we replace large-
volume process equipment with smaller apparatus that output lower, constant volumetric 
flow rates. Continuous operation requires somewhat more time to accomplish for the 
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same relative amount of material to be processed, but at the gain of superior control over 
the product properties. 
 
A workaround for the scale-up problems is to avoid scaling-up the batch apparatus, and 
just use a larger number of batch crystallizers in parallel. This however, leads to much 
greater capital and operating costs, and the problem of batch-to-batch variability [19], 
[24], [47]. This variability results from the fact that even small discrepancies in operating 
conditions can drastically change the physical properties of the obtained crystals [21]. 
There are a variety of causes for this problem, such as differences in feedstocks [21], [30], 
[48] (upstream variation), mechanical wear and fouling, and reusing the same vessel for 
multiple processes [49]. These changes can alter the hydrodynamic and/or heat and mass 
transfer characteristics of the equipment slowly over time, thus altering the CSD obtained 
from a particular vessel. 
 
Lastly, despite the simplicity of the equipment, batch crystallizers are highly complicated 
nonlinear systems [19], [38], [40], [50], [51], and complex dynamic behavior arises with 
increasing complexity of the crystallizer network. Tavare has compiled an expansive 
table of dynamic phenomena observed in conventional MSMPR systems, which are 
stirred tanks similar to a batch system [51]. Multiplicities of steady-states, oscillations, 
orbits, and limit cycles have all been observed [47], [50], [52], and appear generally to be 
caused by the recycle of re-dissolved fines. Time-dependence of the CSD is highly 
undesirable, since disturbances in the crystallizer can propagate downstream to other 
processes, and render the final product’s quality inconsistent [20], [53], [54]. A 
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continuous approach solves many of these problems, as continuous processes are not as 
difficult to control and scale-up. The analysis of the MSMA-PFC is a step forward 
towards the “blue sky” vision of fully continuous, automated drug manufacture by 
streamlining a crucial separation step. 
 
To summarize, particulate processes in the drug industry are poorly understood; this goes 
for not only crystallizers but also dry-powder-phase processes and liquid-powder 
processes. The drug industry is looking to remedy these problems by shifting to the more 
economical continuous mode of operation. This motivates our study into new crystallizer 
designs, that can produce high-quality crystals consistently with much less severity of 




2.2 Overview of Technologies for Continuous Pharmaceutical Manufacturing 
The pharmaceutical industry is modernizing its research, manufacturing, and logistical 
operations. The technologies discussed in section 2.1.1 are almost entirely run in batch 
mode currently, which is inefficient at the pharmaceutical industry’s economy of scale. 
Research effort is increasingly being done toward continuous pharmaceutical 
manufacturing (CPM). Several industry-academic partnerships have appeared to develop 
technologies along this line, such as the Novartis-MIT Center for Continuous 
Manufacturing [23], [55], and the Center for Structured Organic Particulate Systems [9], 
[56]. These technologies snap a panorama of the chemical engineering corpus, and are 
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highly inter-disciplinary, such as the continuous feeding of powders, continuous  
blending, freeze-drying and granulation [9], [28], [29], [31], [57]. The work by Mascia et 
al. [23] at the MIT group is a good summary of the benefits possible with continuous 
manufacturing. That work discusses a variety of improvements their continuous tablet 
plant has made over conventional batch, especially in the reduced number of unit 
operations and an 84% reduction in plant residence time. This research has great potential 
benefit in reducing manufacturing costs, increasing product quality, and improving 
consumer safety. Preliminary estimates of the impact of CPM show cost reductions 
between 25%-40% [5], [20], [23], or higher [19]. Equipment efficiencies of 30% are 




2.2.1 Quality-by-Design (QbD) Thinking 
Variability is a ubiquitous problem in contemporary pharmaceutical processes [19], [48]. 
Raw material variations in composition can affect the yield of API produced during 
chemical reaction, as well as contamination. Variability in excipient properties is a 
serious problem as well, [48], [58]. Even though these components contain no API, 
excipients are added to alter the physical properties of the final dosage form; especially 
the dissolution rate. Variation in particle size distribution, composition, and other 
properties of an excipient can lead to off-specification FDFs [48]. The pharmaceutical 
industry’s current approach to handling off-specification product is to simply throw the 
batch out, which increases costs and environmental impact. 
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The variety of possible FDF’s, tight constraints on product quality, high manufacturing 
costs, and wide variability in final products has motivated the introduction of Quality-by-
Design (QbD) thinking into pharmaceutical process design. Strongly encouraged by the 
FDA [35], Quality-by-Design (QbD) is a methodology for reducing product variability 
during manufacturing. Through a complete process understanding of inputs, outputs, and 
disturbances, and a list of target specifications for the final product, it becomes possible 
to “build quality into” the final product [59]. When successfully implemented, product 
specifications are very likely to be on-target at the end of the process [34], [60]. Our own 
work directly relates to the concept of variability as shown in CHAPTER 4 and 
CHAPTER 5, where the mathematical framework we developed was used to directly 




2.2.2 Critical Quality Attributes and Critical Process Parameters 
Wu et al. [9] discuss the concept of QbD at length in their comparison of chemical 
engineering successes and opportunities in the pharmaceutical and semiconductor 
industries. QbD involves defining the product fully in terms of critical quality attributes, 
or CQA’s. CQA’s are primarily linked to product requirements and safety, but can also 
be tied to other important “marketing” type characteristics, such as having the proper 
color or shape. Then, the proposed manufacturing process is studied in detail using 
models, experiments (especially design-of-experiments, or DOE, approaches [1], [34], 
[61]), and other prior knowledge [62], to identify the critical process parameters (CPP) 
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that impart the most variability  into the final product. A CPP may also be an important 
process disturbance. The collection of process inputs and CPP’s defines the “control  
space,” within which we capable of hitting any of the accept CQA’s in the “design space.” 
In our work , an example of the CQA would be the size of the produced crystals, while a 
CPP would be any of the flowrates.  Further discussion of CQAs and CPPs is given by 
Bondi and Drennen [34].  The QbD archetype stands in contrast to the traditional method 
of Quality-by-Testing (QbT) for pharmaceuticals, where large samples of drug products 
are destructively tested at the end of the process, while still failing to test the quality of all 




2.2.3 The Problem of Quality-by-Testing 
Figure 3.1 below demonstrates the inadequacy of Quality-by-Testing. In Figure 2.2, each 
colored square represents an allotment of drug that has been randomly selected for 
quality-assurance testing. When performing lot testing, the samples taken for analysis are 
obviously checked, but their sibling products are not, and are merely assumed to be safe 
or dangerous based on the results of sampled ones. In Figure 2.2(a), the random selection 
has worked as intended – some of the contaminated samples are discovered, deeming the 
lot unsafe. However, in Figure 2.2(b), the random selection has chosen solely on-
specification samples, but several contaminated ones evade detection. Bear in mind, that 
all of the samples in Figure 2.2(a) would be rejected – not just the two off-specification 
samples identified. This problem neatly demonstrates the goal of QbD – to eliminate the 
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need for off-line testing by tightly controlling all variability in the process, with 
continuous monitoring and logging of all product properties from entrance-to-exit. In this 
manner, the entirety of the released drug product is tested and guaranteed to be safe, at far 
lower cost than using repeated off-line testing. Currently, testing is done a priori using 
analytical techniques such as near-infrared spectroscopy [48] and nuclear magnetic-
resonance spectroscopy [30]. However, since feedstocks are usually natural products [30], 
there are many potential sources of variability [58], and it is impossible to eliminate them 
all. Given measurements of feedstock properties, it can be difficult to know what process 
adjustments should be made to achieve a consistent final dosage form. The correction of 
this variability by advanced process control strategies and novel process designs are some 





Figure 2.2 (a) Depiction of pharmaceutical lot testing. Blue samples are safe, but brown 





2.2.4 QbD and Crystallization 
Crystallization is a key operation in drug manufacture. In crystallization, one typically 
desires large crystals with little size variance – or more generally, desires a certain CSD. 
As we have mentioned previously, crystallization is typically near the beginning to the 
middle of the flowsheet. There is significant interaction between the CSD obtained 
during crystallization, and the efficiency of other downstream process operations. Proper 
development of crystallization processes can provide much greater control over these 
important properties earlier in the process, making downstream processing much easier – 
or eliminating certain unit operations altogether. At the same time, it can also greatly 
improve the drug’s final quality. Batch crystallizers, as discussed in section 2.1.4 have 
serious shortcomings in the way of scale-up, monitoring, control, and product consistency, 
making it difficult to apply QbD to the full drug manufacturing process. This motivates 
the development of more novel crystallization technologies, with better control over 
crystal quality and more economical scale-up [21]. To summarize, proper control of 




2.2.5 Process Analytical Technology 
Process analytical technology (PAT) encompasses a variety of advanced mathematical 
tools, data management methodologies, and chemical analysis equipment that aid in the 
production of safe, cost-effective drugs via improved process observation [36]. One 
might consider PAT to be the evidence-based analog of drug manufacturing, compared to 
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“evidence-based medicine” in the practice of medicine [34], [63].  Bondi and Drennen 
[34] bring up the simple but astute point that, unlike virtually every other product a 
consumer might use in his daily life, he has no idea whether the medicine he is using is 
working or not. It is critical that drugs released to the public not only be safe, but actually 
work as intended using proven scientific methods. This is hardly the case with the drug 
industry today, which relies heavily on end-product testing and strict adherence to master 
recipes as a means of quality assurance [32]. We discuss several definitions which will be 
of benefit to the reader. From Yu et al. [64]: 
• In-line: Real-time measurement of the process material as it is being processed. This 
is the ideal method of observing a CPM process. 
• On-line: Process material must be diverted to analysis equipment, but is still 
monitored during the process. 
• At-line/Offline: Process material must be taken elsewhere for analysis. This is the 
standard manner in which pharmaceuticals are tested. At-line refers to analysis at the 
manufacturing site, offline is elsewhere. Both are undesirable, as they are slow, 
expensive, and a risk factor for process contamination. 
• Invasive: An observation probe must be in contact with the process for a reading to 
occur. This situation is unfavorable for obvious safety and health reasons. There are 
also problems associated with fouling of the sensor, chemical attack, and laborious 
cleaning and sterilization processes. 
• Non-Invasive: No probe is necessary. A reading can be obtained without any contact 
with the process material. 
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The Venn diagram in Figure 2.3 illustrates which of these qualities belongs to various 
types of analytical chemistry tools. Monitoring of pharmaceutical and crystallization 
processes is generally difficult, and significant technical challenges exist in practical 
implementation of these apparatus for adoption by industry. Non-invasive process 
analytical technology (PAT) sensors are highly favored by regulators and industry, since 
there is less direct contact with the process material. The Venn diagram in Figure 2.3 
below shows the relationship between the previous categories and the current 
technologies in use  [13], [64]–[71]. Clearly, there is a dearth of noninvasive sensors. The 
extensive table in Scott and Wilcock mentions virtually every process involved in drug 
manufacture except crystallization [32]. Process analyzers for pharmaceutical 
manufacturing are an active field of research, and crystallization is not the only subfield 
of CPM where new sensors are being developed. Gradinarsky et al. investigated the user 
of a coaxial microwave probe sensor for the measurement of moisture content in a wet 
granulator [72]. The use of new PAT sensors for the monitoring of chemical reactions, 
granulation, and freeze-drying have been reviewed extensively by Scott and Wilcock [32]. 
Concentration (more generally, supersaturation) is a critical variable in for monitoring in 
crystallization processes, since nucleation and growth are direct, strong functions of the 
supersaturation [37]. Sensors such as FTIR [37] and Raman spectroscopy can feasibly 
measure concentration. FTIR is also suitable for simultaneous measurement of multiple 
concentrations in a multi-component mixture. Raman spectroscopy is particularly 
attractive, due to the non-invasive nature of the instrument. Particle vision measurement 
is probably the most intuitive to understand of all the analytical techniques discussed here 
– essentially, the technique is simply taking pictures of the crystals, and visually 
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computing sizes and shapes. However, the image analysis algorithms used to accomplish 
this physically are complicated. Furthermore, very high solids concentrations will make 








































































































































































































































































































2.2.6 Real-Time Monitoring and Real-Time Release 
Real-time PAT monitoring and control abrogates the need for costly post-hoc rejection 
testing, and makes feasible the concept of real-time release (RTR), e.g. where the drug is 
ready to be packaged and distributed as quickly as it is manufactured, with its quality 
assured [73]. Implementation of PAT for real-time monitoring, feedback control of CPPs 
(e.g. concentration, purity, temperature, etc.) would permit adjustments within the design 
space as necessary to keep the product on-spec [13]. This would be a boon to the drug 
industry, which currently requires about 95 days to turn input raw materials into a final 
dosage form [32]. RTR also has the significant advantage over batch testing, since the 
entire drug product being sold has actually been inspected. As reported in Scott and 
Wilcock, to obtain similar levels of quality assurance with rejection testing would 
increase the cost of drugs by about 20% [32]. 
 
Besides inspecting the entire drug production run, online monitoring also has the 
potential to do a better job. This is because end-product testing can only detect serious 
deviations from normal quality and high contamination. Furthermore, end-product testing 
can only detect bacteriological contaminants that will grow in available biological media 
reasonably quickly. Online sensor monitoring using PAT tools (e.g. spectroscopy) would 
be significantly more sensitive to contamination or disturbances than end-product testing. 
A challenge in crystallization, is the development of sensors that can function without 
causing contamination, and can operate correctly despite the presence of a liquid and 
dispersed solid phase.  
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2.2.7 Multivariate Statistical Methodologies 
The complex nature of pharmaceutical manufacturing and crystallization in particular, 
sometimes make first-principles modeling very difficult, or outright infeasible. In such 
situation, multivariable statistical “black box” modeling methods can be helpful. Such 
methods do not seek to match inputs to outputs from a contrived model, but only to find a 
model that does match by use of experimental data. Techniques such as partial least 
squares (PLS) and principal component analysis (PCA) can use ostensibly unrelated 
measurement data to infer and predict system properties [59], [71]. PCA and PLS are 
useful tools as well for “data-reduction”, which is very helpful when dealing with the 
“data avalanche” typical of CPM processes [13], [74]. Such tools have been used for 
some time the field of chemometrics [13]. As shown in Bondi and Drennen, methods 
such as principal component analysis (PCA) can be useful quality assurance parameters, 
capturing the effect of many variables into a single number, whose deviation from a 
certain value is a red-flag that something is amiss [34]. The solution of overdetermined 
systems of equations and redundant measurements can be used to create “soft sensors”, 
which are not actual hardware sensors, but instead are a mathematically-sophisticated 
state observer [71], [75]. Soft sensors can reconcile large amounts of measurement data 
with the governing equations to infer an optimal estimate of the true value of the data (e.g. 
the Kalman filter [75]). By utilizing multiple measurements of completely different 
natural phenomenon, a more accurate state estimate can be obtained. We cover only 
small portion of the “CPM-metrics” field here, as the body of literature is extensive. 
Other methods, such as design-of-experiments (DOE), response surfaces, and Bayesian 
statistics are discussed elsewhere in the literature [59]. A major challenge in modeling of 
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crystallization processes is in accurate estimation of their kinetic parameters. Wong et al. 
[76] have used an artificial neural network to model the crystallization kinetics of lactose, 
including the agglomeration effect. Using first principles to develop a model including 
the effect of stirrer speed would have been very difficult. Wu et al. [77] used a full 
factorial design (33) and a combination of linear regression models and a neural network 
to investigate and model the co-precipitation of naproxen (Aleve™) and Eudragit™. 
Other works have focused on dimensional reduction, which is a very powerful method for 
simplifying the data analysis, control, and fault diagnosis [59], [78], [79] of experiments 
involving CPM processes. Tomba et al. applied a multivariate statistical framework for 
organizing and analyzing data from a granulation and tabletting process [59]. PCA was 
used extensively in that work to identify dominant variables amongst a large possible set, 
in order to properly identify critical process parameters. Routinely a space of 10 or more 
variables could be described with only 2 or 3 principal components. Such an approach 
can be highly useful in CPM processes. The thesis by Cipich discusses the use of several 
multivariate tools for the detection of systematic (“gross”) errors in a continuous tablet 
pressing process [29]. In that work, several statistical tests are used for fault detection, 




2.2.8 Technologies for Powders, Particles, and Tablets 
While this work is focused mainly on crystallization, it is important for the reader to have 
an understanding of the CPM field as a whole. Over 80% of drug FDFs are oral tablets, 
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which are manufactured by blending API with powder-phase excipients and pressing 
them [29], [80]. Proper control over crystal properties is necessary to achieve a good 
press. Oral tablet FDF’s have a variety of manufacturing difficulties caused by the 
complicated interactions within multicomponent powder mixtures. Powders possess 
properties significantly different from the bulk phase. Particle modification processes are 
often necessary to ease handling, such as wet or dry granulation. Such powder systems 
are difficult to mathematically model, and cannot be realistically modeled as fluids. 
Kleinbudde [28], Vervaet and Ramon [31], and Pernenkil and Cooney [57] have 
reviewed the processing of pharmaceutical powders in depth. A vast amount of research 
has been done on process design, modeling, and simulation of pharmaceutical powder 
processes. We present a brief summary of the research on solid pharmaceutical 
processing in Table 2 below. Boukouvala et al. [81] modeled and simulated continuous 
blending processes for the homogenization of two-powder mixtures. Four-dimensional 
population balance models have been used to track the distributions of size, composition, 
liquid content, and porosity of particles within a wet granulator [25]. The discrete 
element method has been used to examine the variability in film properties of liquid-
coated tablets in rotary coating equipment [82]–[84]. Sinha et al. used finite element 
methods borrowed from the field of soil mechanics to investigate the compaction of 
























































































































































































































































































































































































































2.2.9 Pharmaceutical Informatics 
 
Figure 2.4 Conceptual diagram of CPM implementing PAT for real-time release of final 
drug products. Information collected from analytical chemistry equipment (among other 




Pharmaceutical informatics is the application of management information systems (MIS) 
tools to the observation and improvement of pharmaceutical manufacturing processes and 
quality control [13], [32]. Figure 2.4 above illustrates how the large amounts of data that 
can be collected from monitoring tools are another route for implementing QbD and 
continuous improvement. Informatics and data mining methods are useful for finding 
unforeseen process defects and rapid fault correction [86]. The enormous amounts of data 
produced and demanded by the pharmaceutical supply chain forms a complicated data 
management problem. Venkatasubramanian [74], [87] and Zhao [88] discuss 
pharmaceutical informatics in greater detail. Further discussion of information 
management/big-data analytics applied to pharmaceutical manufacturing is beyond the 













Data is stored for analysis. Can 




2.2.10 Process Control 
The last major topic for review is a discussion of the optimization and process control of 
CPM processes, in which continuous crystallization is utilized. In the manufacture of 
chemical products, a proper control system is vital for ensuring process stability and 
safety. This is especially true in the drug industry, since not only plant personnel but the 
customer depend on the proper operation of controllers. For smaller-scale processes, 
separate control loops for each unit operation provide a simple method for controlling the 
entire process. However, for much larger plants and production levels, the number of 
control loops can reach into the thousands, and there can be a significant amount of 
detrimental interaction between different unit ops. The optimal control strategy for the 
process as a whole will be much different (and significantly more efficient) than a 
strategy that is optimal unit-op-by-unit-op. Model-based control of batch and continuous 
crystallizers is reviewed in [86], [89]–[91]. This problem of plant-wide control (PWC), 
refers to the choices of controlled variables, manipulated variables, what measurements 
will be made, and what types of controllers will be used [92]. It is a problem of immense 
difficulty and practical importance, and its difficulty is compounded by the presence of 
disturbances and uncertainty in process parameters, as well as the fact that the optimal 
control structure can shift with time due to market conditions [92], an issue of great 
importance to the pharmaceutical industry. Plant-wide optimization and plant-wide 
control has been applied extensively in other areas of the chemicals industry. Challenges 
arise in the full optimization of CPM flowsheets, due to the complexity of the models 
used to describe underlying physical phenomena. Among other methods, an optimization 
approach can be applied to PWC, by sifting through possible control structures in some 
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fashion, simulating the plant with the generated structure and assumed disturbances, and 
then calculating a scoring function based upon the observed dynamic and steady-state 
performance (typically profit maximization.) In general, this is a difficult constrained 
combinatorial optimization problem (generally, a mixed-integer nonlinear programming 
problem, or MINLP), requiring a great deal of computing power to iteratively simulate 
the plant. CPM processes are especially difficult to rigorously optimize due to model 
complexity. There are a variety of computational difficulties related to fast and accurate 
solution of the model equations involved. In addition to solving the mass and energy 
balance equations for the plant, the population balance equations must also be solved for 
relevant unit operation. Powder processing operations, such as granulation, blending, and 
tablet coating, require costly discrete element method (DEM) simulations to model 
correctly, as mentioned in section 2.2.8. This problem stymies the use of rigorous 




2.2.11 Specific Examples of Plantwide Simulation, Control, and Optimization 
A review of various plant-wide control methodologies is given by Vasudevan and 
Rangaiah [93]. In that work, one can observe a variety of industrial chemical processes 
for which PWC has been applied; none of these are pharmaceutical processes. Clearly, 
there is a limited amount of literature available on the subject. However, an important 
result from the literature studies discussed here is that parameters upstream from the 
process can have a significant impact on the quality of the final drug product. Mascia et 
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al. utilized a two-layer approach to control system design for their continuous tablet 
manufacturing pilot plant [23]. One layer was used for stabilization, whilst the other was 
for controlling quality. The stabilization loop kept each unit operation within its specified 
bounds, while the quality controller focused on guiding the process to ensure the 
produced tablets met quality standards. They present data that demonstrate process 
resilience against disturbances. Lakerveld et al. examined the use of optimal average 
level control to control disturbances in a buffer tank downstream from a crystallizer and 
upstream from a chemical reactor. The exit concentration and outlet flowrate of the buffer 
tank was used to stop the propagation of disturbances from affecting the downstream 
reactor. The overall work shows robustness is an important requirement for effective 
control of a pharmaceutical process. Sen et al. [53] reported results for modeling and 
simulation of a continuous pharmaceutical process. The process consisted of a continuous 
cooling crystallizer, filter, fluid-bed dryer, and screw blender process for production a 
final drug product. Using a dynamic PBM-DEM (population balance model-discrete 
element method) model, they investigated the effect of various parameters on the 
homogeneity of the API-excipient mixture produced by the blender. As expected, altering 
the cooling profile of the crystallizer changes the output crystal CSD. However, the 
different CSDs obtained showed a different dynamic response in the API content of the 
blended drug formulation, with some profiles being more sluggish than others to reach 
the desired final value. Suggested in their study, optimization of the cooling profile could 
produce a faster result in the blending process, decreasing the amount of wasted product. 
Benyahia et al. [20]  performed a much larger dynamic flowsheet simulation. A CPM 
pilot plant was simulated using a sophisticated dynamic model, totaling 104 differential 
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equations and 2 × 103 algebraic equations. The simulated plant produced drugs directly 
from scratch; taking in raw reactant material at the entrance, and producing coated tablets 
at the exit. The effect of changing raw material, excipient, and equipment parameters 
upon the final product purity was experimented with via simulation. Impurities emanating 
from the first reactor in their flowsheet were found to have a significant impact on the 
performance of the entire process. Ward et al. [91] have developed a plant-wide control 
approach for a combined process consisting of reaction in a CSTR, MSMPR 
crystallization, and then filtration with liquid recycle back to the CSTR. While not 
explicitly applied to pharmaceutical processes, the scenario is general enough to warrant 
discussion here. Despite being able to find well-performing control structures for the 
process, some would require real-time monitoring of CSD (or average size) as well as 
supersaturation, with no measurement error or time delay. While various monitoring 
setups have been demonstrated in the literature for measuring supersaturation and CSD, 
this is generally not the case in industry. Finally, a different problem was solved 
altogether by Levis and Papageorgeiou [33]. In that work, the investigators formulated a 
large mixed-integer linear programming (MILP) problem for large-scale optimization of 
an entire pharmaceutical enterprise. The problem was to optimize over a choice of 
possible products, how the geographically-distributed manufacturing network would be 
set up, what sales goals would need to be met, and how much inventory to hold on hand, 
subject to a large number of constraints, for a time span of 13 years (3 years of clinical 
trials, 10 years of profitability). This work demonstrates the combinatorial nature of 
decision-making pharmaceutical manufacturing management. It is interesting to note that 
the time required to scale-up a process is explicitly incorporated into the problem 
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formulation. The work also demonstrates how much the geographical distribution of 
operations complicates decision-making in the drug industry, and suggests how much 




2.2.12 Uses of Simulation 
As mentioned previously, an important issue in the design of CPM processes is 
understanding how different unit operations interact with each other, either regarding the 
change in location of the steady-state with various parameters, or transient interactions in 
their dynamics. Simulation is of great usage in the study of chemical processing plants. 
Related to pharmaceutical manufacture, even slight variations in an upstream process (or 
more likely, a feedstock), could propagate in a highly counter-intuitive fashion 
downstream, rendering the final drug product ineffective or unsafe. Dynamic models 
permit analysis of transient responses, allowing one to see how long the process requires 
to reach steady state [1]. This is especially important in drug manufacture, as API is often 
expensive to waste, and precise quality is required [5]. Programs such as gPROMS and 
PARSIVAL have been used in the literature for such simulation work, along with 
custom-written programs [53], [94]. In this work, we have opted to write our own 
software in MATLAB for simulating and optimizing the crystallization process. 
 
To summarize our thoughts on continuous pharmaceutical manufacturing (CPM), a 
variety of technologies are being researched in this field. By using process systems 
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engineering concepts for planning the process combined with real-time monitoring and 
control, variability in the final product can be greatly reduced or eliminated altogether. 
Quality-by-Design (QbD) is a manner of designing the process as such that all variability 
is minimized, eliminated, monitored, and controlled. Batch crystallization is a barrier to 
implementation of QbD, since batch processes impart uncontrollable variability into the 
final product. A variety of new analytical sensors are being designed in order to enabled 
noninvasive, continuous on-line and in-line process monitoring. Multivariate statistical 
methodologies are also being applied as “soft sensors”, where knowledge of model 
equations and a known set of observations can be used to refine the current state estimate. 
Population balances, finite element methods, and discrete element methods have been 
applied to the difficult matter of modeling solids processing operations, such as wet/dry 
granulation, tablet pressing, tablet coating, and of course, crystallization. Plant-wide 





2.3 The Basic Science of Crystallization 
Crystallization can affect important physical properties of drug products, such as 
enantiomeric excess, polymorphic composition, and CSD (see Shekunov and York [21]). 
These variables are directly related to either the dissolution rate, or in the case of 
enantiomeric excess, whether the drug is therapeutic or outright toxic. Table 3 below 
discusses the type of impact that crystallization can have on the final drug properties, as 
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well as the current degree of control capability. The table also shows how certain 
properties may impact the process heavily, but not the curative properties of the drug, and 
vice versa. This is especially true of enantiomeric form, which has virtually no impact on 
the process, but can mean the difference between producing an effective drug or a deadly 
toxin. 
 
A short tutorial on crystallization can be found in [38], and the review article by Chen [24] 
discusses matters specific to pharmaceuticals. Work by Jones [40] and Tavare [51] focus 
more on engineering aspects. The science of crystallization is discussed at length in the 
review article by Dirksen and Ring [95], as well as books by Desiraju et al. [96] and 
Davey and Garside [97]. The basic principle behind crystallization is to alter the ambient 
conditions of the liquid solution (such as by cooling, evaporation, or drowning out) so as 
to create a solution which is holding more solute than the solubility limit would prescribe. 
Such a liquid is known as a supersaturated solution, and supersaturation is the driving 
force for the nucleation and growth of crystals. Figure 2.5 below depicts the solubility 
curves for antisolvent and cooling crystallization. Before discussion antisolvent and 






















































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.5 Antisolvent addition and cooling crystallization methods, and illustration of 
the solubility curve. The metastable zone is the supersaturation limit at which primary 





• Below the solubility curve, dissolution occurs. The solution is undersaturated. 
• On the curve, the crystals are in equilibrium with the liquid phase. The liquid phase is 
said to be saturated. 
• Above the solubility curve lies the metastable zone, where crystal nucleation and 
growth occur. Here the liquid phase is said to be supersaturated, and the distance 
above the solubility curve is known as the supersaturation. Nucleation occurs here 
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• Above the metastable region lies the limit of the metastable zone (also known as the 
labile region). In this region, nucleation is triggered immediately. 
Supersaturations above the metastable boundary can result in amorphous solids and oils 
[43]. While gas-phase crystallization is possible, industrial practice is typically confined 
to a liquid phase, especially concerning pharmaceuticals [98]. Crystals are produced by 
creating a supersaturation ( ) within the API solution. A variety of phenomena can be 
employed to create a supersaturation. Here we introduce the two most-common methods 




2.3.1 Antisolvent Crystallization 
Antisolvent crystallization (left in Figure 2.5) is performed by adding a second liquid to a 
saturated solution in which the solute is much less soluble. Addition of this this second 
liquid, termed the antisolvent (also termed the co-solvent or diluent), gradually reduces 
the solubility of the mixture, generating a supersaturation. Manipulation of pH can also 
work in this fashion [99]. The ordinate of this solubility curve is the solute concentration, 
and the abscissa is usually either the mass fraction or volume fraction of antisolvent in 
the mixture. The upper and lower bounds on possible antisolvent mass fractions, of 







2.3.2 Cooling Crystallization 
Cooling crystallization (right in Figure 2.5) exploits the temperature-dependence of 
solubility. In this method, a saturated hot solution is rapidly cooled, which decreases 
solubility, and hence generates a supersaturation. The lower and upper bounds on 
temperature are the freezing point of the solution ($"##)# ), and the decomposition 
temperature of the API molecules ($%#&'( ). If $%#&'(   is very low, then cooling 
crystallization becomes impractical, which motivates the use of the antisolvent method. 
While the discussion of additives and impurities is beyond the scope of this work, it is 
worth mentioning that solubility curves can be sensitive to impurities even down to the 





2.3.3 Other Methods 
Antisolvent, cooling, and vacuum crystallization represent the overwhelming majority of 
industrial crystallization methods in practice, but there are some more rare methods used 
or encountered in nature. An arcane example is high pressure crystallization. This method 
has been used specifically for the separation of mixtures of cresols by using high 
pressures to manipulate the melting points of the individual cresol species in the mixture 
[51], [100]. Evaporation is another crystallization method. Under moderate heating, the 
liquid phase can be driven off by evaporation, which causes a rise in solute concentration 




“crystallizer.” A combination of evaporation and cooling can be done in tandem with 
vacuum crystallization, which applies suction to the system to more rapidly remove 
vaporized solvent. A much rarer example is reverse osmosis. Reverse osmosis can also be 
used to generate a supersaturation by the expulsion of the solvent across a semipermeable 
membrane. While almost never used for practical crystallizations, reverse osmosis 
crystallization is known to precipitate kidney stones and gallstones in the human body 
[51]. More recently discovered methods of generating supersaturation utilize bubbles 
from dissolved gases, electric fields, and lasers. Rungsimanon reports the use of focused 
lasers to crystallize γ-glycine, with subsequent dissolution upon deactivation of the laser 
[101], [102]. Similar results are reported by Yuyama for L-phenylalanine [103]. The 
references in Llinas and Goodman [99] discuss laser nucleation in greater depth. Aber et 
al. report the use of strong electric fields to trigger nucleation of γ-glycine in aqueous 
solution [104]. Knott et al. report a variety of results related to their work on triggering 
crystal nucleation of aqueous glycine by shaking dissolved argon gas bubbles out of the 
solution [105]. Ultrasound-induced crystallization [99]. While the mechanism is still 
unknown, it is conjectured that the collapse of cavitation bubbles causes a large local 
increase in temperature. This creates a great increase solubility, followed by subsequent 
cooling from contact with the bulk solution, generating a large supersaturation. Narducci 
et al. [106] have experimented the use of ultrasonic waves for shape control of adipic acid 
particles. In both continuous and batch mode, smaller, rougher, spherical crystals were 
produced than other methods – such as wet milling. The authors suggest improved 




2.4 Kinetic Processes in Crystallization 
 




An understanding of the basic kinetic processes is essential to understanding 
crystallization. The diagram in Figure 2.6 above summarizes the important kinetic 
phenomena in crystallization processes. More detailed discussion of crystallization 
kinetics can be found in [97], [107]–[109]. Supersaturation provides the driving force for 
nucleation and growth; the greater the supersaturation, the higher the rates of nucleation 
and growth. Supersaturation is some measure of the quantity   in Figure 2.5. However, 
supersaturation goes by a variety of monikers. The most commonly encountered 





Supersaturation difference, or commonly “the supersaturation” is given by: 
 ∆ =  −  (2.1) 
Where  is the solute concentration (kg/m3 or kg/kg solution), and  is the solubility 
concentration (the dark curve in Figure 2.5). 
The dimensionless “supersaturation ratio”: 
  = / (2.2) 
Or lastly the “relative supersaturation” 
  "# = ( − )/ (2.3) 
As we shall see in the further sections, greater supersaturation leads to faster rates of 





Nucleation is a fundamental process in crystallization. In nucleation, new crystals are 
formed due to a supersaturation. Nucleation can occur in a variety of ways, such as 
primary, homogeneous, hetereogeneous, and secondary modes. The exact mechanisms 
for growth and nucleation are currently not well understood [24], [47]. The most common 
theory is that of nuclei or classical nucleation theory. Upon reaching a certain critical 
radius, incipient crystals (termed “embryos”) no longer dissolve back into solution, but 
continue to grow and form a crystal lattice. Nucleation rate increases not only with the 




cluster formation depends on the probability of solute molecule collisions, which increase 
monotonically with increasing solubility. Hence, a lower supersaturation is required to 
achieve a given nucleation rate at a higher solubility [110]. Furthermore, nucleation rate 
is dependent on liquid viscosity, since greater viscosities impart greater diffusional 
resistance from solute particles interacting with a cluster [110]. 
 
Primary nucleation is any nucleation process in which no crystals are initially present. In 
any supersaturated solution is a large collection of liquid-phase molecular arrangements 
with the potential to become crystals, termed embryos. The transition from embryo to 
crystal requires passage over a free energy barrier. The energy barrier to crystal formation 
is formed by two opposing thermodynamic processes. First is the unfavorable process of 
increasing the surface area of a new phase (e.g. the crystal). Secondly is the favorable 
process of a solute molecule transitioning from the liquid phase and integrating into a 
new solid phase. Once an embryo reaches a critical radius, c&, the free energy barrier 
rolls downhill. Once this occurs, crystal formation becomes spontaneous, and a new 
crystal pops into existence. The theory of primary nucleation is explained in more detail 
elsewhere ([40], [97], [109], [111]). 
 
Homogeneous nucleation occurs when crystals nucleate directly within the bulk phase of 
the solution, away from interfaces such as vessel walls and suspended impurities. 
Homogeneous nucleation is only achievable under highly contrived experimental 
conditions, and is almost never observed in nature. It also requires very high 




large. Small droplets dispersed within a two-phase immiscible flow are one such way to 
experimentally observe homogeneous nucleation [110]. Large volumes ( > 100 µl [110]) 
are typically incapable of homogeneous nucleation, since impurity contamination is too 
difficult to control. 
 
More commonly encountered is heterogeneous nucleation, where nuclei form on external 
surfaces in contact with the liquid phase. Foreign particles and vessel walls are typical 
nucleation sites. When no seeds are present in the solution, no extra surfaces are available 
for nucleation. This leads to a nucleation law of the form: 
  = 89 9 (2.4) 
Where  is the nucleation rate (#/m3∙s), 89 is the nucleation rate constant (#/m3∙s),   is 
the supersaturation ratio (dimensionless), and S is the nucleation order (dimensionless). 
Any of the other definitions of supersaturation described in section 2.4 are also valid with 
(2.4). 
 
When crystals are already present in the system (a “seeded” solution), the extant crystals 
provide extra sources of nucleation. During secondary nucleation, the extra surface area 
provided by the extant crystals possesses more nucleation sites than the solution by itself. 
Furthermore, processes such as shear-induced crystallization and crystal-crystal contact 
can trigger additional nucleation as well. The number of nucleation sites scales upward 
with the content of crystals in the slurry, and thus expressions for secondary nucleation 
include an intensive quantity term for total crystal content. This leads to secondary 




  = 89GI! 9 (2.5) 
Where GI is the 8J moment of the crystal size distribution. Often,  ≈ 1, and 8 = 2 or 3. 
The moments are directly related to the quantity of crystals in the solution, so this 
expression intuitively makes sense (see [111] for a discussion of crystal moments). The 
more crystals there are in the solution, the more secondary nucleation we would expect. 
The units of 89  depend on the values of 8  and  , but the units of   are still #/m3∙s. 
Typical bounds on   are given on page 60 of Tavare [51] as 10e − 10He  #/kg∙s for 
primary nucleation, and 10f − 10H  #/kg∙s for secondary nucleation. Nucleation order 





While some nucleation is required in an unseeded solution to “get the ball rolling”, 
nucleation is generally undesirable in crystallization processes. Crystal growth is the 
main phenomenon we wish to encourage in our crystallization. More growth means 
larger crystals, and larger crystals are generally better. During crystal growth, solute 
molecules integrate, layer by layer, into the crystal lattice. Typically, growth is generally 
bottlenecked by the surface integration step, where incoming solute molecules must 
possess a particular intramolecular configuration to be able to bind properly to the crystal 
lattice. Growth may be diffusion limited as well. While other expressions do exist, as 




 P = 87 7 (2.6) 
Where P is the growth rate (µm/s),   is the supersaturation ratio, 87 is the growth rate 
constant, and T is the growth order. Typical bounds on P are given by Tavare [51] as 
0.001 < iPi < i1 µm/s, and typical bounds on the kinetic constants are 0.001 < i87 < 1 
µm/s, and 0 < T < 3. For size dependent growth, a common expression is [113]: 
 P = 87 7(1 + )( (2.7) 
 
A common feature (and manufacturing difficulty) of pharmaceutical drugs is their very 
slow growth rates and poor water solubility (~100-101 µg solute/g H2O) [114]. 
Pharmaceutical API’s are typically complicated organic molecules with many internal 
degrees of freedom [22], which creates a high entropic barrier to surface integration, even 
when enthalpy change is highly favorable. Growth rate dispersion is the phenomena 
observed where crystals of the same size, under the same ambient conditions, display two 
different growth rates. The root cause of this phenomena is the intrinsic stochasticity of 
crystal growth. The stochastic nature of crystallization is apparent at low liquid volumes, 
where it is possible to observe nucleation in one small volume of liquid, but not in 
another. Likewise, growth rate dispersion is also a stochastic process (or can be modeled 
as such) as solute molecules have a chance associated with themselves at any instant of 
time to choose to integrate into the crystal lattice of a given crystals in the slurry. 
 
Chemical additives can stunt growth along certain directions, leading to a preferred 




crystallizing solution can have a variety of helpful benefits. Typically, one uses additives 
with a similar structure to the subject molecule. The presence of even small amounts of 
additive can change the relative growth rates between various crystal faces, altering the 
crystal’s shape. Additives can also improve the tableting process [21]. The use of 
additives is unexplored territory concerning our work. In this thesis, we have only 
exploited supersaturation as a control, while a more sophisticated scheme for controlling 





The dissolution rate of pharmaceuticals strongly impacts their bioavailability. When an 
oral dosage form is ingested, the excipient binder is digested away in the stomach, and 
eventually discharged to the small intestine. In the small intestine, drug uptake is 
achieved and the drug finally enters the blood stream. However, the degree of uptake is 
dependent on the drug’s concentration at the tissue surface. This of course, depends on 
how well the drug dissolves in aqueous solution. Most pharmaceutical drugs are poorly 
soluble in water, on the order of a few micrograms per gram. The poor solubility and 
dissolution rates have led to many engineering approaches to increase dissolution rate, 
including mechanical micronization, and the production of small crystals and 
nanocrystals, and amorphous forms. Amorphous solid forms are of interest, since they are 





The gray points in Figure 2.5 on page 44 indicate a solution that is below solubility. 
When concentration is below the solubility concentration, the solution is said to be 
undersaturated, which leads to the dissolution of crystals. During dissolution, crystallized 
solute molecules break of and dissolve back into the solution. This causes the solute 
concentration to rise to the solubility curve and attain equilibrium.  Dissolution is 
typically much faster than growth, since there is no surface integration step. Some 
expressions for dissolution from the literature include [113], [115]: 
 O = 8%(1 −  )%k  (2.8) 
The exponent of the dissolution law is usually 1, which makes for much faster “reverse 
growth.” Typically also 8% ≫ 87 . Furthermore, small crystals typically dissolve much 
faster due to the Gibbs-Thomson effect  [116]. CHAPTER 6 incorporates dissolution into 




2.4.4 Agglomeration and Breakage 
Agglomeration and breakage do not consume supersaturation, but affect the CSD in other 
ways. Breakage is typically cause by a moving surface, such as the impeller. 
Agglomeration is caused by high surface energy. Both agglomeration and breakage 
greatly complicate the solution of population balance equations, since these phenomena 




breakage are beyond the scope of this work. A detailed discussion of agglomeration and 




2.5 Polymorphic Form and Chiral Form 
While this thesis is concerned with the control of crystal size, polymorphism is a critical 
quality attribute for pharmaceutical manufacture. We give a brief overview of 
polymorphism in this section, as well as recent developments in observation and control 
of solid forms. Polymorphism has substantial impact on drug discovery, manufacture, and 
efficacy [22], [96], [43], [117]. Some polymorphic forms of an API are more preferable 
for pharmaceutical use, due to faster dissolution rates and higher bioavailability. The 
proclivity of a substance to take on different polymorphic forms during crystallization 
complicates the development, patenting, and manufacture of pharmaceuticals. Desiraju et 
al. [96] discusses several industry case studies that led to lawsuits, recalls, and product 
failure – namely the anti-ulcer drug Ranitidine (Zantac), and  the AIDS drug Ritonavir. 
Generally, the thermodynamically most-stable form is preferred to remove the possibility 








2.5.1 General Background and Properties of Polymorphs 
Solid-phase forms fall into four types: polymorphs, solvates, desolvated solvates, and 
amorphous compounds [21]. While these each have their own nuances that are important 
to product and process development, for brevity we focus only on true polymorphs. Two 
or more different polymorphic forms of a substance possess the same chemical formula, 
but have different molecular packing arrangements that generate the lattice [22], [96]. 
Complicated organic molecules, such as pharmaceuticals, are typically bedeviled by 
several polymorphic forms due to many internal and external degrees of freedom for 
arrangement [99]. While aspirin only has one known form, carbamazepine has four, and 
olanzapine has six [99]. Polymorphism affects a variety of macroscopic properties, such 
as color, density, crystal habit, melting point  [22], [96], [43], [99]. Internal transport 
properties, such as thermal and electrical conductivity, can also substantially differ. 
Furthermore, the surface exposure of certain chemical moieties and crystal faces can 
impart increased chemical reactivity, dissolution rate, and solubility in one form 
compared to another [22], [99], [118]. This is especially true of amorphous solid forms. 
Dissolution rate and solubility directly impact the potency of oral tablets, the most 
popular dosage form [22]. Many common pharmaceutical unit operations (e.g. 
crystallization, freeze-drying, milling) can alter the solid form in difficult-to-predict ways 
[21]. Milling and other size-reduction operations are known to induce polymorphic 
changes in fed crystals [21]. Maintaining target solid-form and while maintaining other 
process variables is also difficult. Reutzel-Edens mentions a study in which the filtration 
and drying produced the desired solid-form of the API, but that solvent removal 




2.5.2 Polymorph observation and control 
While critical to product safety and quality, monitoring and control of polymorphic 
crystallizations is still poorly understood. Both observation and control of polymorphic 
form are major challenges in crystallization [119]. More work is listed therein pertaining 
to other process variables, such as concentration and crystal shape. Raman spectroscopy, 
near-IR, and mid-IR have been used for observation of solid form previously. Indirect 
approaches to polymorph observation and control have been applied [22]. One study 
mentioned in [22] successfully prepared one form of an enantiotropic compound by 
seeding the process with the desired polymorph, and keeping the temperature below the 
intersection temperature on the two solubility curves. Another study inferred 
polymorphic form by the investigators noticing that, for their particular API, the 
formation of an undesired solvate also formed a quasi-emulsion. Studies using particle 
vision measurements (PVM) allowed the research team to identify correct operating 
conditions to avoid the emulsion formation, as well as generating the desired non-solvate 
form. Solid-form can be ascertained by X-ray powder diffraction (XRD), differential 
scanning calorimetry (DSC), relative humidity measurement (%RH), and Laue 
diffraction [21]. Such methods however, are not readily amenable to continuous 
monitoring. Continuous, quantitative control and monitoring of solid-phase form is a 
major research challenge. Some methods for altering the solid-phase form is 
manipulation of the solvent used for crystallization. The solvent used can strongly impact 
the crystallized polymorph [118]. Supersaturation is theoretically useful as a control, 
however, this is only for the production of amorphous forms, and can only be done at 




new method for direct and selective crystallization of certain polymorphs using laser 




2.5.3 Chiral Form 
The enantiomeric form of the molecules composing a given crystal, while practically 
irrelevant to the manufacturing process, can be critical to the final product quality and 
safety [120]. 
 
About 50% of sold drugs are chiral [21]. Chiral crystallization is often difficult and 
expensive to do, rendering many drugs infeasible to produce. A variety of methods are 
possible for controlling enantiomeric form, depending upon what level of separation 
resolution is required. Direct crystallization into two chiral forms (also referred to as 
“preferential crystallization”) can be done by cycling between optically-pure seed crystals 
of each stereoisomer, while avoiding nucleation. Often this method is not possible, since 
crystallization into a solid racemate is often thermodynamically favorable [21]. Other 
methods are also possible for more difficult cases, such as performing the crystallization 
in a chiral compound, or reacting the racemate of the API to create a new substance for 
which preferential crystallization is possible [21]. Selectivity in chiral form can be 





2.6 The Quantitative Framework of Crystal Size Distributions 
During crystallization within solution, imperfect mixing causes spatial gradients in 
supersaturation. These localized gradients, along with the stochastic nature of growth and 
nucleation processes, produces crystals of non-uniform size and shape. To 
mathematically describe these variations in crystal size, one uses the concept of a crystal 
size distribution (CSD). The framework is discussed in exhaustive detail in the books by 
Jones, Garside and Davey, and Randolph and Larson [40], [97], [111]. We present here 
the most crucial aspects for understanding this work. 
 
A characteristic length is a chord piercing through a crystal along an arbitrary direction in 
 . A chord is any line joining two faces of the crystal polytope. For an irregularly 
shaped, nonspherical crystal, (Figure 2.7a) there is no unique chord with which we can 
measure the length of a given crystal. A perfectly spherical crystal (Figure 2.7b) is the 
only crystal which can be uniquely defined with the single characteristic chord length. 
Crystal shape can be described in this way by using multiple length measurements for 
each crystal, yielding a multidimensional CSD [111]. Additional lengths provide more 
information about the crystal size population, at the cost of increasing complexity. The 
distribution of characteristic lengths in a collection of crystals defines the crystal size 
distribution, a critical quantity in assessing the performance of crystallization processes 










Figure 2.7 (a) An irregularly shaped crystal has an infinite number of possible 
characteristic lengths one can arbitrarily choose for measuring its size. (b) The only shape 
possessing a unique direction is a perfectly spherical crystal, for which all of the possible 




2.6.1 Crystal Size Distributions and General Mathematical Properties. 
 


















































The CSD is synonymous with the number density, :() , (#/µm4), where   is the 
characteristic length. This quantity gives the number of crystals between size   and 
i + i/ , per unit control volume. CSD is a critical variable in measuring the 
performance of a crystallization process and the final drug product. Figure 2.8 above 
illustrates a typical CSD, its cumulative summation/integral, and several other quantities. 
Several possible representations of a crystal size distribution are possible. All crystal size 
distributions possess a mean (GH,  in the diagram) and a standard deviation (<). On 
physical grounds, the number density must be greater than zero everywhere, since we 
cannot have negative quantities of crystals. Furthermore, we cannot have negative crystal 
sizes, and so we only consider distributions defined for  > 0. Since we would very 
much like to share this universe with the crystals, we note that limB→r :() = 0. 
 Integration over the entire domain will always give the total number of crystals, per unit 
control volume, in the control volume. A very similar quantity is termed the number 
fraction distribution, 1 (m-1crystals): 
1() = :()s :()/r  (2.9) 
 
Where 1 is the fraction of the total crystal population with a size between  and  + /. 
It is easy to show that s 1/r = 1 . We note that the integrals of any fractional 





2.6.2 Volume Size Distributions 
Many analytical instruments do not measure number density, but instead measure volume 
density, :; (m3crystals/m3external∙mcrystals), given by: 
 :;() = 86:() (2.10) 
 
Where 86 is a dimensionless shape factor (t 6v  for spheres), and :; is the volume of the 
crystals of size  to  + /. The total volume of all the crystals, per unit of control 
volume, is given by  = s :;/r . Analogous to the number fraction distribution is 
the volume fraction distribution, 1;: 
 1;() = :()

s :()/r  (2.11) 
Just like the number fraction distribution, s 1;/r = 1. A variety of other distributions 
can be defined, such as mass and area fraction. Area fraction is especially important when 
studying chemical reactions on the surfaces of particles, as the exposed area is where the 
chemical reaction occurs (either for a direct reaction with the particle surface or a 




2.6.3 The Impact of Crystal Size Distribution and Crystal Properties 
The CSD is known to impact the efficiency of further downstream processing steps (e.g. 




forms [24], [37]. It also strongly affects the dissolution kinetics within the human body, 
which impact final product quality and safety [21], [37], [122]. There are a variety of 
benefits from producing a proper CSD in the produced crystals, such as high 
bioavailability and improved tablet stability [21], [37], [49]. Furthermore, good control of 
CSD can abrogate the need for various size-reduction processes, such as milling, that are 
commonly used in drug manufacture [24], [37], [49]. Generally in crystallization, one 
desires the largest crystals possible. Large crystals make downstream processing 
operations, such as washing and filtering [97], much easier. For some applications, 
extremely small crystals are preferred. The use of nano-sized crystals in drug products is 
a possible work-around to the poor solubility of many of today’s drug APIs [123], as well 
as for the production of inhalable powders and injectable suspensions [21]. In both cases 
however, a narrow CSD is often preferred. More generally than the CSD, a variety of 
other crystal properties affect drug performance as well. Table 3 on page 43 summarizes 
these properties, the motivation for wanting to control them, and how much 
controllability exists in the current state-of-the-art [21], [24], [38], [40], [86], [89], [96], 




2.7 Population Balances 
Most chemical engineers are familiar with the four main balance equations in chemical 




individually, and instead direct the reader to any of the textbooks ([126]–[128]) for an 




= w rateiofiΨienteringtheicontrolivolume − w rateiofiΨileavingtheicontrolivolume
+ w rateiofiΨigeneratedinsideitheicontrolivolume
− w rateiofiΨiconsumedinsideitheicontrolivolume 
(2.12) 
Where Ψ  is any of the four quantities previously discussed. However, the two main 
equations of mass and energy balance are not sufficient to model particulate processes. 
The main reason for this is due to an infinite number of populations that can close the 
same mass balance. Figure 2.9 illustrates the problem geometrically. In the diagram, a 
given mass of raw material is operated upon by a process, producing a product. In (a), 
both the raw material and product are monolithic. However, in (b) the raw material and 
product are discrete particles of different sizes, which have the same total mass as the 
original blocks in (a). If individual sizes are important variables, mass and energy 
balances alone are not capable of modeling this phenomena; any number of chopped-up 









 This is not a problem that can be approximated away or swept under the rug. Particle 
phases are widely encountered in engineering processes, and the properties of the 
collective population of particles is often critical to ease of processing, and final product 
quality [47]. Ignoring the momentum and entropy balances, a third balance equation is 
required in addition to the mass and energy balance. This third balance is important to 
pharmaceutical manufacture, since particulate phases are so common in pharmaceutical 
production. The operations of crystallization, granulation, tableting, etc., produce crystals, 
granules, and tablets – all involve discrete particles. The population balance gives a third 
conservation law for describing the internal property distribution of populations of 
entities. A population balance model (PBM) neatly summarizes all of the operations 
occurring in a system that affects the number of particles with a particular set of 
characteristics residing within the control volume, such as birth, death, agglomeration, 








framework has been used to model all sorts of interesting phenomena involving discrete 
particles, such as biological cells, sterilization processes [47], [131], aerosols, solid rocket 
engines [111], and polymerizations [47], [131], [132], pharmaceutical granules, purity of 
pharmaceutical crystals, and enantiomeric excess of pharmaceutical crystals. The 
equation is given by: 
i :
 + E#> ∙ (:) + E0 ∙ (Z:) +  + O = 0 
(2.13) 
Where : is the number density (#/m4), t is the time,  is a vector of external velocities, Z 
is a vector of internal velocities (crystal growth rates),   is the birth function (e.g. 
nucleation, breakage), and O is the death function (e.g. breakage, agglomeration). Both  
and O have units of #/m4∙s. The two gradients are taken with respect to either the external 
coordinates (@, V, and W), or the internal coordinates (H, H, …, ' for and crystals with 
m characteristic lengths). The general population balance equation is a partial differential 
equation [111], and solution is generally difficult. Solving this equation coupled with the 
other balance equations yields the correct CSD. The equation was first proposed in 
Hulburt and Katz [133]. Good introductions to the formulation and solution of these 
models are found in the books by Randolph and Larson [111], Jones [40], Garside and 
Davey [97], and Ramkrishna [132], as well as the paper by Rawlings [47]. While the 
mass balance equation is typically an ordinary differential equation (ODE), PBMs are 
partial differential equations (PDE), which are significantly more burdensome to solve. 
Solution of crystallization systems is generally difficult for several reasons –the large 
number of variables, vast differences in time and length scales, and the inherent 




agglomeration [37], [134]. To solve these equations, we discuss two important methods 




2.7.1 The Method of Moments (MOM) and Finite Volume Method 
Due to the mathematical structure of PBMs, it is possible to reduce them to a system of 
ODEs by an integral transformation known as the “method of moments.” This is a widely 
used method for solving PBM equations, and is popular due to the rapidity of solution. 
The 8J moment of the crystal size distribution is given by: 





The moment form of the population balance equation is formulated by taking the 8J 
moment of the equation, which expresses the original PBE solely in terms of GI [111]. 
Instead of a partial differential equation, 8 + 1 ordinary differential equations need to be 
solved (the extra equation is the mass balance). This problem is significantly easier to 
solve than the original. We discuss this method in greater detail in section 4.4.2. 
 
While easier to solve, the MOM loses the CSD in its entirety, making prediction of the 
full CSD impossible. Such information is needed for applications such as matching a 
target CSD. Furthermore, depending on the phenomena being modeled, the method of 
moments may lead to the “closure problem”, where the 8J  moment equation is 




use of a variety of other integration methods for solving moment equations, such as the 
quadrature method of moments. Accurate solution is done by decomposition to a large 
system of ODEs, using the method of weighted residuals or the finite volume method. 
The finite volume method has been applied to the modeling of a multi-segment plug flow 
crystallizer previously by Alvarez and Myerson [135]. Number density may itself be a 
function of external position, motivating the use of combined CFD-PBM models. The 




2.7.2 More Sophisticated Population Balance Modeling Approaches 
There has been much work done with computational fluid dynamics (CFD) simulations 
using special software packages, to clearly examine what the flow patterns are within the 
crystallizers. These models involve not only the population balance equation, but the 
fluid transport equations as well. The k-ε model has been used to investigate turbulent 
effects [40]. While these simulations do provide useful data in the form of shear profiles, 
temperature profiles, and the location of solids in the crystallizer [44], they are time-
consuming to run, and the countermeasures one can take on scale up are still limited. 
Furthermore, if prediction of changes to the CSD is desired, a combined CFD-PBM 
simulation is required, to account for spatial variation in particle number density. Such 





Essentially all phenomena in crystallization are random in some way. Nucleation, 
breakage, growth, and agglomeration are all based on some chance encounter between 
either two particles, or a particle and a molecule for growth, or an ensemble of molecules 
for nucleation [139]–[141]. Monte-Carlo methods are based on using computer-generated 
random numbers to simulate physical random (or presumptively random) phenomena. 
Braatz has discussed several papers which utilized stochastic PBM models and were 
solved with MC methods [37]. MC methods are able to model this type of phenomena in 
fine detail, but are computationally burdensome. We note that MC is a general tool, and 
has been applied to crystallization in other ways to crystallization other than solving the 
PBM equation. Jones has described the use of MC to explicitly account for a residence-




2.7.3 Current Challenges in Continuous Crystallization and Population Balance 
Modeling 
Challenges abound in the application of process systems engineering knowledge to 
pharmaceuticals. This thesis fills an important literature gap by addressing the need for an 
integrated modeling, optimization, and design framework for the identification of optimal 
crystallizer designs. This framework can be applied to many other crystallization systems 






Currently, general solution of the population balance equation is not known, and 
numerical methods tend to exhibit significant tradeoffs in speed and accuracy [134]. 
Speed is required for utilizing the model for model-predictive control, and accuracy is 
required to make the benefits of optimal control worthwhile. 
 
Related to the issue of robustness is the issue of dynamic stability. Due to the high 
nonlinearity present in crystallization systems, the effect of time usually requires 
numerical solution to observe on the CSD. In MSMPRs, oscillations in the CSD are a 
known and undesirable phenomena. Dynamics in general have been studied for the 
conventional batch and MSMPR crystallizers, as well as networks of MSMPRs. However, 
newer crystallizer designs, such as the MSMA-PFC, have not had such analyses done for 
them. Furthermore, in newer crystallizer designs (such as the MSMA-PFC), it is 
unknown what type of dynamic behavior may be present, e.g. limit cycling or chaos. 
Bifurcation analysis of such systems is nearly impossible to do analytically. Rigorous 
computational studies are one method addressing this literature gap. 
 
Another challenge, separate from the mathematical difficulties, is the issue of parameter 
estimation. The full description of the process requires a great deal of information [40], 
including solubility data, crystal density, liquid transport properties, crystal growth rate(s), 
and nucleation rate [40]. Accurate estimation of kinetic parameters for growth, nucleation, 
and dissolution is one of the most difficult hurdles to surmount in constructing an 
accurate crystallization PBM [37], [47]. As pointed out by Rawlings [47], the results 




be sensitive to experimental error. Without very accurate parameter estimates, all of the 
effort expended upon optimizing the crystallization equipment and process operation may 
be for naught, with virtually no benefit realized. This goes not only for continuous 
crystallization, but the entire CPM flowsheet. Model complexity becomes even more 
acute when phenomena such as size-dependent growth, non-uniform residence-time 
distributions, agglomeration and breakage, and growth-rate dispersion are added to the 
model [47]. The complicated nature of such models has motivated the use of Monte-




2.8 Multiobjective Optimization in Crystallization Design and Research 
We have utilized multiobjective optimization extensively in our work in CHAPTER 4. In 
preparation for this chapter, we provide the reader with useful background information on 
multiobjective optimization. Multiobjective optimization is a generalization of scalar 
optimization which accounts for the common situation when the decision maker has 
multiple conflicting objectives he wishes to optimize over. In general, global 
optimization of each function at the same time is unattainable [142]–[144], thus 
motivating the concepts of Pareto optimality, trade-off, and non-dominated solutions. 
This framework has been applied to batch crystallization by several workers [120], [145]. 
Such a framework appears quite applicable to analysis of PFCs, since it provides detailed 
information on what CSDs are attainable. Bhat and Huang [120] applied the approach to 




objectives for maximization, in addition to maximizing size, while minimizing  and 
batch time. Sarkar et al. [146] simultaneously extremized several quantities, and supplied 
Pareto frontiers. 
 
Typically in crystallization control, one desires larger crystals with compact shape, since 
these have superior filtering and dry properties. However, sometimes smaller crystals, 
which dissolve faster, are preferable. The purpose of this section is to give the reader a 
brief background on the subject of multiobjective optimization (MOO) and discuss 
several important issues related to the practical solution of MOO problems. This section 
draws heavily from the books by Deb [147], Gen and Cheng [148], and Chambers [148], 
which give in-depth discussions of evolutionary algorithms applied to multi-objective 




2.8.1 Basic Problem Formulation 
The standard formulation for an MOO problem is: 
i
:3 1H(3) 1f(3) ⋯ 1'(3) 
Subject to: 
\(3) ≤ 






Multiobjective optimization is a natural consequence of the fact that real problems, 
especially in engineering, often cannot be characterized in terms of a single objective. 
Frequently, we must optimize over a variety of objectives, such as capital cost, operating 
cost, volume, weight, energy consumption, and other objectives specific to a particular 
problem. No single design can simultaneously optimize all objectives in the vector.  
2.8.2 Pareto Optimality and the Pareto Frontier 
The Pareto-optimal (or also, “non-dominated”) set of solutions to an MOO problem is the 
MOO analog of the global minimum for a single-objective problem. Due to multiple 
objectives though, the solution is expressed as a set of points instead of a single point. 
These points describe a curve, called the Pareto frontier, for which a tradeoff exists 
between any two points on the curve. When a point lies on the Pareto frontier, moving in 
any direction leads to a desirable reduction in one objective and a concomitant, 
undesirable increase in another objective. In mathematical terms, the globally-optimal 
Pareto frontier satisfies the property that: 
i 1∗(3) ≤ 1(3) (2.16) 
for all feasible 3 and for all 1, 2, . . . ,  objectives. That is, there is no point that can 




2.8.3 Use of the Genetic Algorithm 
Many methods exist for solution of problem (2.15), which depend on the difficulty of the 




are of little use in crystallization problems. The most direct method for solving an MOO 
problem is by stochastic optimization. Many such schemes exist, such as simulated 
annealing, bacterial foraging, ant-colony, and particle-swarm optimization. In this work, 
we have used the genetic algorithm (GA), which mimics the Darwinian process of natural 
selection to generate the Pareto frontier. In the GA, a pool of solutions are first generated, 
and the objective function is evaluated for each of them. The “fittest” solutions are 
allowed to pass on to the next generation. Then a variety of mutation, transposition, and 
selection operators create a new set of “child” solutions created from the “genes” of the 
parent solutions. This helps preserve the good qualities of the prior solutions, but offers a 
chance to improve the solution further by moving elsewhere in the search space. Unlike 





CHAPTER 3. CURRENT LITERATURE ON CONTINUOUS 
CRYSTALLIZATION TECHNOLOGIES 
We present in this chapter a more specific literature review focusing solely on continuous 
crystallization designs that have been proposed and tested in the literature. The purpose 
of this chapter is to expose the reader to the breadth of the continuous crystallization 
literature. It also helps place our work in the greater context, as we have investigated in 
this work solely the MSMA-PFC. A handy table at the end of this chapter summarizes the 





3.1 The MSMPR, MSMPR Cascade, and CoFlore™ Crystallizers 
The mixed-suspension, mixed-product removal (MSMPR) crystallizer is the workhorse 
of large-scale chemical manufacture, used for productions of ~1-50 tons/day [47]. It is 
the crystallization analog of a continuous stirred-tank reactor (CSTR). Large, scaled-up 
examples of such devices can be seen in Larsen et al. [38]. Aside from large-scale use, 
the MSMPR (as well as batch crystallizers) is used often in the laboratory for 
experimentally determining growth and nucleation rates, and also for detecting size-




Mascia et al. utilized MSMPRs for their crystallizations in their study of a continuous 
tablet manufacturing pilot plant [23].Quon et al. [149], Zhang et al. [150], and Alvarez et 
al. [151] demonstrate the use of multiple MSMPR’s in series for cooling and antisolvent 
crystallization of pharmaceuticals. Newer MSMPR technologies have explored novel 
new mixing methods to allow for better process control. A highly intensified version of 
the MSMPR cascade is the CoFlore™ reactor, which has been recently applied to the 
continuous reactive crystallization of N-iodomorphlonium salt by Browne et al. [152]. 
Originally developed for chemical reactions, the CoFlore™ reactor utilizes several 
agitated compartments, along with bulk agitation with a linear oscillator, to keep solids 
suspended while crystallization is taking place [152]. A major problem with continuous 
crystallizers of all kinds is the issue of plugging and fouling, and high shear mixing is one 
method of forestalling buildup. Unlike larger MSMPRs, the smaller Coflore™ 
crystallizer offers superior mixing characteristics, enabling swift mass transfer and 
avoiding the problems with solid suspension discussed in section 2.1.4. Narducci et al. 




3.2 Plug-Flow Crystallizers 
The plug-flow crystallizer (PFC) is analogous to the plug-flow reactor (PFR). It can be 
shown analytically that the MSMPR cascade, in the limit of infinitely small CSTRs, 
asymptotically converges to the PFC [154]. Cascades generally converge to a PFC within 




require too great of a residence time (and thus too slow of flow velocity) to be useful. A 
common feature of plug-flow crystallizers (and other types discussed in §3.3) in the 
recent literature on pharmaceutical crystallization is the exploration of various mixing 
methods. Among others, we observe vortex mixers (“Roughton” type [155]), impinging 
jets [136], [137], [156], and static mixers (e.g. the Kenics mixer [135]). Such mixers have 
been investigated for flow-dependent reaction syntheses previously, and more recently 
for use in crystallization research. The topic of static mixers is discussed at length in the 
review by Thakur et al. [157]. Generally, such mixers are found to be significantly more 
efficient than active mixers, and, with proper design, can rapidly achieve plug flow. 
Typically, good mixing can be achieved using vortex mixers, or static helical mixers. 
Simulations by Woo et al. [136] show that vortex mixers possess mixing times well 
below the induction time of crystallization, which ensures that there are no confounding 
effects from supersaturation gradients. Eder et al. [158], [159] have investigated a stage-
wise cooling PFC for continuous aspirin crystallization. Their PFC consists of a flexible 
coiled tube, which permits a long residence time, but occupies little space.  Control over 
the supersaturation trajectory is achieved by chilling separate coiled sections. This 
permits the creation of a clearly-defined temperature profile along the length of the PFC. 
For the case of antisolvent crystallization, The plug flow crystallizer is often not a 
practical tool for pharmaceutical crystallization, since residence times must be so long to 
achieve a larger crystal size. This leads to very low flow rates and low velocities, which 
leads to settling of the crystals and fouling of the inner surfaces with API. Very low flow 
velocities also lead to self-contradiction if the “plug-flow” crystallizer is operated in the 




pulsating “thumper” to drive flow continually back and forth, while maintaining a net 
positive forward flow. The logic in using these baffles is to obtain better turbulent mixing 
along the length of the crystallizer, while avoiding high flow rates which would normally 
be necessary to produce it. High velocity is achieved without shortening residence time. 
FBRM was used for observation of crystal size via chord-length distribution. Their 




3.2.1 Multi-Segmented Plug-Flow Crystallizers 
A feature of this thesis is investigation into using multiple crystallizer segments in series. 
This allows for spatial control over supersaturation in on dimension, which is not possible 
in a stirred tank (batch or continuous) crystallizer. Variation of supersaturation with 
length allows for improved control over growth and nucleation, which leads to a better 
final crystal product. Prior work in this area has been done by Alvarez on antisolvent 
crystallization, Majumder and Nagy on the modeling of cooling crystallization, and 
Ridder et al. on modeling antisolvent crystallization. Alvarez and Myerson have 
investigated a multi-segment PFC, with separate antisolvent injections into each stage 
[135]. Their segmented PFC system was modeled with a set of PBM equations and a 
mass balance equation, and compared to experimental results. The kinetic and solubility 
parameters of ketoconazole, flufenamic acid, and L-glutamic acid were determined 
experimentally for use in the model. FBRM was used for measuring CSD, and comparing 




type static mixer was used to ensure good homogenization of the liquor and antisolvent 
streams, but other approaches have been used as well. Majumder and Nagy investigated 
the use of in-situ dissolution in plug-flow cooling crystallization in order to eliminate fine 
crystals [113]. Ridder et al. investigated the crystallization of flufenamic acid via a 
simulation and optimization-based study [161], [162]. The sensitivity to kinetic 




3.3  Other Types of Continuous Crystallizers 
Nguyen et al. [163] have investigated the use of this crystallizer. In a CT crystallizer, 
liquor flows into the hollow gap between a cylindrical shell and a concentrically-located 
spinning cylinder. When rotated at high speed, the fluid eventually exhibits Couette-
Taylor flow, where the fluid segregates into an “accordion” of concentric toruses, with 
fluid rotating concentrically about the axes of the individual toruses rather than about the 
axis of the spinning cylinder. Unlike the COBC, which directly compartmentalizes 
various elements of fluid, each torus might be considered its own “compartment”, and 
mixing occurs within toruses as well as between them. These toruses can be modeled as 
separate compartments in a compartment flow model. The CT crystallizer allows for high 
slurry velocity, which improves mixing and avoids the problems of settling and fouling at 
low velocity. However, residence time can be controlled purely by inlet flow. Thus a 





A type of spray-drying crystallization using electrically-stimulated liquid jets has been 
investigated by Wang et al. [123] for the production of carbamazepine nanocrystals. 
Similar to spray-drying, an electrospray device generates fine jets of liquid by applying 
electric potential to a saturated liquid solution. The charged fine droplets naturally repel 
each other in flight, until they land on a grounded surface. Rapid evaporation leads to 
amorphous crystals. This approach is interesting, in that it provides a continuous 
production route to a particular (though, in this case, unstable) solid-form, in the nano-
sized regime. Significantly more work could be done in terms of modeling of this system, 
such as population balance modeling of the generated droplet cloud.  
 
Another design is the electrospray crystallizer. This type of device, originally developed 
for plastic injection molding, utilizes two opposing streams of high-velocity liquid 
sprayed at an intersecting point. The region where these two streams collide creates a 
zone of intense mixing, avoiding the aforementioned trouble with supersaturation 
gradients. Details about the design of this crystallizer can be found in the original patent 
[156]. The Braatz group at MIT has done extensive work on the modeling, simulation, 
and optimization of this type of crystallizer [136], [137] for the case of the drug lovastatin 
and L-histidine. Woo [136] performed combined CFD-PBM-micromixing simulations of 
the impinging jet crystallizer within the mixing chamber. Their results show that, given a 
sufficiently high Reynolds number, thorough mixing is achieved before fluid exits the 
mixing chamber. The results of that study were further used in [137], where the obtained 
crystal size distributions from the previous modeling were used as decision variables in 




a series of quadratic programming and nonlinear least squares optimizations were solved 
to identify the optimal control strategy for seed input into a CSTR. By adjusting jet 
velocity as a function of time, a variety of peculiar CSDs were obtained. Their numerical 




3.3.1 Continuous Microcrystallizers 
Borrowing from the field of chemical reaction engineering, is the concept of the 
microcrystallizer [164]–[166]. Due to the aforementioned problems with crystallizer 
scale-up, an alternative approach is to use multiple, smaller continuous flow devices in 
parallel. Once a single microreactor has been design and tested thoroughly, the process of 
scale-up to a larger mass flow rate is greatly simplified, as multiple units can be used in 
parallel instead of enlarged. This is termed “number up”, as opposed to “scale-up.” 
However, the technical problems of fluid distribution and lack of flexibility in inputs 
leaves “number up” can still be challenging for proper scale-up [167]. Microcrystallizers 
have pharmaceutical use as high-throughput screening platforms for drug discovery and 
development, and lab-scale process optimization [167].  Currently, they are not usable for 
drug production, due to plugging and fouling of the vessel interior [167]. Microfluidic 
crystallization is mainly used for high-throughput screening of optimal experimental 
procedures for protein crystallization. However, use has been demonstrated for high-




cite a case where over 2000 screening experiments were performed for polymorph 
identification using only 2 grams of API [99].  
3.4 Table of Continuous Crystallization Technologies 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 4. MULTIOBJECTIVE OPTIMIZATION AND ROBUSTNESS 
ANALYSIS OF THE MULTI-SEGMENT, MULTI-ADDITION PLUG-FLOW 
ANTISOLVENT CRYSTALLIZER (MSMA-PFC) 
4.1 Abstract 
In this chapter, we present optimization and simulation results related to a new type of 
crystallizer for the production of pharmaceutical APIs. We develop the population 
balance and mass balance model framework, as well as the multiobjective optimization 
framework for investigating the design of the crystallizer. The governing model equations 
are derived and presented. Landscape plots of mass-mean size () and coefficient of 
variation () indicate great sensitivity to flowrate and nonconvexity, necessitating the 
use of stochastic optimization via the genetic algorithm. Using multi-objective 
optimization, we calculated optimal designs for this crystallizer in terms of maximizing 
 and minimizing . A tradeoff exists between these two quantities. Mean size was 
improved over prior literature results while maintaining similar spread. The optimal 
solution was sensitive to uncertainty in the kinetic parameters of nucleation (89) and 
growth (87). Lastly, we have investigated the sensitivity to flowrate for the MSMA-PFC 
using a simple Monte-Carlo technique. The greatest sensitivity is observed in the first and 
third segments, while the second and fourth have little process impact. This work is 
substantially composed of work from the paper [161]. Adapted with permission from B. J. 




Optimization of a Multisegment Multiaddition (MSMA) Continuous Plug-Flow 
Antisolvent Crystallizer,” Ind. Eng. Chem. Res., vol. 53, no. 11, pp. 4387–4397, Feb. 
2014. Copyright 2014 American Chemical Society. It also contains work substantially 
composed of from the conference paper [162]. Adapted with permission from B. J. 
Ridder, A. Majumder, and Z. K. Nagy, “Population balance model based multi-objective 
optimization and robustness analysis of a continuous plug flow antisolvent crystallizer,” 






As discussed in CHAPTER 1, financial pressures have caused the pharmaceutical 
industry to express interest in the development of new manufacturing technologies [3], 
[7], [15]. These problems translate into high manufacturing costs, though little attention 
has been historically paid to the problem. One such technology branch that is being 
researched is advanced crystallization processes. Crystallization is a major separation unit 
operation in fine chemical and pharmaceutical manufacture. The overwhelming majority 
of drugs are organic molecules crystallized from solution [24], [113], [169]. 
Predominantly, pharmaceutical crystallization is done batch-wise, despite clear evidence 
of the economic advantages of continuous manufacturing – such as steady-state operation, 





An optimization problem has been indirectly suggested in the literature by Alvarez and 
Myerson [169]. Alvarez had attempted to improve the crystal output properties by 
manipulation of injection configuration and/or antisolvent flowrates in an MSMA-PFC. 
In previous work on batch crystallization, the goal was to manipulate supersaturation as a 
function of time to achieve an optimal set of crystal properties at the conclusion of the 
batch [145], [146], [170], [171]. Analogously in this work, we have manipulated the 
supersaturation profile in order to optimize the crystal properties at the outlet. The 
difference is that the supersaturation profile in the batch case is with respect to time, 
while here it is with respect to length into the crystallizer. 
 
We have optimized an MSMA-PFC for the production of flufenamic acid, an anti-
inflammatory drug [169], [172]. By altering the antisolvent flowrates in the various 
sections, the supersaturation can be controlled along the length of the crystallizer. The 
supersaturation within a segment strongly affects the nucleation and growth kinetics 
therein and thus gives us a method for manipulating the product CSD at the outlet. The 
process is modeled using a steady-state population balance model (PBM), and is solved 
using the method of moments as well as a high-resolution finite volume scheme [113], 
[173], [174]. A similar work has been performed by Vetter et al. [17] In that work, the 
authors investigated the attainable product regions of crystal size for a given residence 
time in continuous crystallizers. Such studies are helpful in estimating the performance 






To investigate this continuous flow system, we utilize a multi-objective optimization 
(MOO, also known as “vector optimization”) framework. Such a framework is useful for 
fully investigating the capabilities of particular design. The solution of MOO problems is 
cast in terms of finding the non-dominated set of possible solutions, e.g., the solutions for 
which it is impossible to improve one objective without degrading another. This non-
dominated set is referred to as the “Pareto frontier.” Such a framework is highly 
amenable to crystallization problems, which often have a multitude of conflicting 
objectives in the problem definition. MOO has been applied previously to batch 
crystallization processes [145], [146]. We explore the multi-objective optimization (MOO) 
of the MSMA-PFC, with the objectives of maximizing the mass-mean size () and 
minimizing the coefficient of variation (). We show in this work that nonconvexities 
are encountered in the search landscape, making a stochastic optimization algorithm more 
appropriate. A widely-used solver for finding the Pareto front is the non-dominated 
sorting genetic algorithm (NSGA-II), which can efficiently identify the non-dominated 
set, and handle constraints[175], [176]. We also investigated the sensitivity of the Pareto 
front to uncertainty in the kinetic parameters. The simultaneous design and control 
framework for the MSMA-PFC is evaluated and it is shown that with appropriated 
crystallizer design, that takes the possibility of improved control into account, can 




4.4 Model Diagram, and Governing Equations 
 




The idea behind the MSMA-PFC is to distribute antisolvent along the length of the 
crystallizer, which allows for the control of supersaturation in one dimension. The 
MSMA-PFC is based on the setup in Alvarez and Myerson [169]. It is modeled as a 
series of ideal plug flow elements, and antisolvent is added at the beginning of each 
segment (see). Each of the  segments is a separate PFC.  is the antisolvent flow rate 
added to the Jisegment. The inlet at the far left is the feed flow rate (##%), with an 
initial concentration of solute () and a seed crystal size distribution (CSD), :. The 
population and mass balance equations are solved for each segment, and the output of 
one segment becomes the input to the next segment. The CSD (:) and concentration () 
are adjusted for the dilution induced by the addition of antisolvent. The final CSD, :, is 
used for formulating the multi-objective optimization problem. The optimization problem 
is solved by manipulating the antisolvent flow rates in each segment (). It is assumed 




















































operation. The solvent and antisolvent streams are assumed to mix together perfectly, and 
attain plug flow. In this work, we consider only the unseeded case (: = 0); however the 
same framework can be applied for seeded operation. The population and mass balance 
equations are solved for each segment, and the output of one segment becomes the input 





4.4.1 Model Equations 
The model equations for the crystallizer design explained above consist of a set of 
population balance equations (PBEs) describing the evolution of the CSD along the array 
of plug flow crystallizers, coupled with mass balance equations that take into account the 
depletion of solute concentration in the solution due to crystal growth and nucleation. 
Population balances are a key tool in the model-based control of crystallizers [40], [51], 
[70], [97], [124], [177]. In this work, our seed distribution at the inlet is zero; the process 
is unseeded. Number density changes along the tube length since birth and growth 
processes depend on the supersaturation ( ). The model equations for the steady-state 
system are discussed below. The PBE for a PFC is derived by crossing off the irrelevant 
terms in the general equation given in (2.13):  




Since we are using the average velocity, => @v = 0. If one-dimension flow is assumed, 
then the other two velocity components are zero. We assume size independent growth, 
e.g. P v = 0. Regarding the birth function, only nucleation occurs, which means only 
crystals of size   enter the system. This is modeled using a Dirac delta function as 
 = F( − ), whereiF( − ) has units of m-1. There is no death function here, e.g. 






 = (!)F( − ) (4.2)  
 where the superscript  denotes the J segment of the MSMA-PFC, =>(!) is the average 
velocity of the fluid, :(!) is the number density, and @ is the length along the crystallizer. 
The average velocity is computed by adding up the total volumetric flow rates of solvent 
and antisolvent in the particular PFC segment, and dividing by the cross-sectional area of 
the PFC. In the PBM literature,  is referred to as the “internal coordinate”, while @ is 
referred to as the “external coordinate.” Our boundary conditions are [111]: 
:(!)(0, @) = (!) P(!)v  (4.3) 
 
:(!), @!,0 = !:(!H), @!H, (4.4) 
 
and :(H)(, 0) = 0 (e.g. the process is unseeded). Furthermore, (!) is the nucleation rate, 
P(!) is the  crystal growth rate and ! is the dilution factor.  At the entrance of each PFC 
segment, the CSD and solute concentration were adjusted by multiplying with a factor 




! =i##% + 
!H
##% +  ! . (4.5)  
This factor is derived by performing a mass balance around all PFC segments and mixing 
points up to and including the Ji PFC segment ( = 0, and  = 1ifor the first PFC 
segment). Equation (4.2) tracks the CSD as solution passes through the PFC array. In 
addition to eq. (4.2) the solute mass must be tracked. We do this by simultaneously 
solving the mass balance equation: 
=>(!) /
(!)





wherei(!)  is the concentration of dissolved solute in the liquid phase, K&  is the solid 
crystal density, and 86  is the crystal shape factor.  decreases along the length of the 
array via not only the processes of growth and nucleation, but also by addition of fresh 
antisolvent. Thus, the mass balance boundary condition is (@ = 0) = i and 
(!)@!,0 = !(!H)@!H, (4.7) 
 
Equation (4.6) accounts for the depletion of dissolved solute from the supersaturated 
liquid phase by the layer-by-layer areal deposition of solute matter upon the exterior 
surfaces of nucleated crystals. Other ancillary equations are, the growth and nucleation 
rate equations: 
P(!)( ) = 87( (!))7,      ( ) = 89( (!))9, (4.8) 
 




*+%(!) = 100  +
 ¡¢
 + ¡¢ i£i¤¢
  ,     (!) = (!) − (!)  ,   (!) = ¥@^(−*+%(!)), (4.9)  
Where   is the supersaturation, 87 , T , 89 , and S  are growth and nucleation rate law 
parameters, *+% is the antisolvent volume percentage,  is the solubility concentration, 
and  and  are fitted parameters for the solubility curve. The solubility and kinetic 
parameters used in this work are those regressed by Alvarez and Myerson for flufenamic 
acid [169]. Numerical values for the parameters discussed here are given in Table 5 

















Table 5 Parameters for crystallization optimization from Alvarez and Myerson [169]. 
Copyright 2014 IEEE. 
Parameter Value 
Inner diameter, m 1.27i × i10 
Initial concentration, , mg/m3 1.24i × i10¨ 
Solubility parameter, , mg/m3 3.36i × i10© 
Solubility parameter, , dimensionless 0.108 
Shape factor, 86, dimensionless t/6i(≈ i0.524) 
Crystal density,iK&, mg/m3 1.47i × i10« 
Mother liquor flowrate, , ml/min 100 
Segment length, m 0.6 
Growth rate constant 87, m/s 9.9i ×i10¨ 
Growth law exponent, T, dimensionless 1.1 
Nucleation rate constant 89, #/(m3·s) 1.5i × i10© 
Nucleation law exponent, S, dimensionless 2.1 
Antisolvent concentration in initial solution (mg/m3) 0 
 
 
4.4.2 Solution of Model Equations 
Depending on the application or desired information, some solution methods are more 
appropriate than others. Typically various method of moments (MOM) are used to solve 
the population balance equations (PBEs), when only moments of the CSD are required, 




(QMOM) [134], [178]–[180]. The importance of moments lies in the convenient 
simplifications they impart to the solution of crystallizer modeling equations [40], [111], 
[181]. In the method of moments, progressively higher moments of (2.13) are taken, 
reducing the complicated, coupled, ODE-PDE system to a system of  + 1 ODE’s; the 
 moment equations, plus the mass balance in (4.6). The 8J  moment of the CSD is 
given by: 





The physical meaning of the moments is straightforward: G  is the total number of 
crystals, GH their total length, Gf their total surface area, and G their total volume – all 
per unit of control volume [111], [181].To obtain the moment form of the PBE, first take 





















= (!)I  (4.12) 
 
The term s :(!) v I/r  can be integrated using integration by parts to finally obtain 
the 8J-moment equation: 
/GI(!)/@ =
8P(!)GIH(!) + (!)I
=>(!)  (4.13)  
The full system of MOM equations is given by plugging in 8 = 0,1, … ,5 into (4.13): 





/GH(!) /@v = wP(!)G(!) + (!) =>(!)°  
/Gf(!) /@v = w2P(!)GH(!) + (!)f =>(!)°  
/G(!) /@v = w3P(!)Gf(!) + (!) =>(!)°  
/G(!) /@v = w4P(!)G(!) + (!) =>(!)°  
/G±(!) /@v = w5P(!)G(!) + (!)± =>(!)°  
/(!) /@v = −3K&86P(!)Gf(!) =>(!)°  
This set of equations provides the steady state moment model of the MSMA-PFC. This 
technique permits rapid solution in terms of moments, but loses the full CSD. The MOM 
requires computationally much cheaper function evaluations, making it more efficient in 
the optimization which requires multiple iterations within the genetic algorithm. These 
seven equations solve for two important average quantities at the exit of the MSMA-PFC. 
The exit ( = ) mass-mean crystal size is given by: 
 = G() G()°  (4.15) 
 
and the exit mass-mean coefficient of variation is given by: 
 = ²G±()G() (G())f° − 1 (4.16) 
 
The first six moments (0 through 5) were solved for, since these are required to fully 
calculate (4.15) and (4.16). 
 
The main drawback to this approach is that knowledge of the full CSD is lost during the 




system, where Q is the number of bins in the reconstructed CSD. There can be substantial 
numerical difficulty in calculating moments of very high order, since the calculation 
requires the number of moment equations to be equal to (Q − 1). Figure 2 in McGraw 
[178] shows increasing deviation from the exact solution for increasing 8, for the case of 
GH through G±. Also, this Q × Q system is typically ill-conditioned, meaning that even 
slight changes in the matrix elements can dramatically change the uncovered CSD [111]. 
The method also cannot be used when the lower moments are functions of higher ones - 
solution becomes impossible since closure of the equations is never attained. This 
“closure problem” occurs when more complicated terms are used for the modeling of 
growth, breakage, and agglomeration [182]. For this reason, simplistic terms for growth, 
such as constant or linear size-dependence, are commonly used in the literature – and also 
why breakage and agglomeration are typically neglected. 
 
However, other methods can circumvent this problem and allow us to solve for the full 
CSD. Various solution approaches are available to solve the PBEs for the full CSD, such 
as the high resolution finite volume (FV) technique [113], [173], [174], weighted 
essentially nonoscillatory (WENO) [183], [184], finite element method (FEM) [185], 
[186], method of characteristics (MOCH) [183], [187], Lattice-Boltzmann method (LBM) 
[188], [189], and Monte Carlo method[190], [191]. In this work the PBEs were solved 
using a high resolution FV technique, which is the combination of the semi-discrete FV 
technique with the van Leer flux limiter, for its efficiency and ease of implementation 
[113], [173], [174]. The method discretizes (2.13) into Q ordinary differential equations, 




progressed upward in 4 µm increments, for 249 additional increments, up to the 
maximum bin size of 998 µm, for a total of 250 bins. Just as in the MOM case, the mass 
balance equation (4.6) is also solved. This technique can capture the sharp front without 
numerical oscillations and provides at least second-order accuracy where the solution is 
smooth. 
 
To summarize the two solution methods, the MOM method entails solving 7 
simultaneous ODE’s, while the FV method requires solving 251 .  The greater speed 
(about 1/16th the wall-clock time of the FV method) of the MOM method makes it more 
appropriate for solving the optimization problems. The moment-transformed equations 
were solved using MATLAB’s ‘ode23’ solver, while the FV equations were solved using 
Runge-Kutta numerical integration (‘ode45’ in MATLAB). In our approach we used the 
fast MOM method with the genetic algorithm to decrease the computation time for 
finding the optimal antisolvent profiles and crystallizer design, and then used the FV 




4.4.3 Multi-Objective Optimization Problem Formulation 
The multiobjective problem formulation follows that given in section 2.8.1. With regards 
to our system,  and  are strong functions of the antisolvent flowrate vector, X, and 
manipulating Xiwill change Y. While there are some instances in which small crystals are 




CSD (low ) with a large mean size (highi). To solve the MOO problem, we used 
MATLAB’s implementation of the non-dominated sorting genetic algorithm (NSGA-II), 
‘gamultiobj’, to search over X for the non-dominated set, since it is found to work well 
for solving similar type of optimization problems[146], [192]. For eachiX, the model 
equations discussed in the previous section were solved. The final result from the last 
crystallizer segment was used to calculate the objective function values.  and  for 
:(, @#0%) were calculated using:  
Y = ³1/ii´ , (4.17) 
where 1/i is used because `gamultiobj’ seeks to minimize functions. The actual 
decision variables used in the optimization were fractions of a required total antisolvent 
flowrate: 
! = =! i, (4.18) 
 
where =  is the decision variable manipulated by the genetic algorithm for the jth 
crystallizer segment, and   is the total required antisolvent flowrate. An equality 
constraint forced these percentages to sum to 1: 
µ=! i
!
= 1 (4.19) 
 
Each individual decision variable was also bounded between 0 and 1: 








4.5 Results and Discussion 
4.5.1 Nonconvexity of  and CV Landscapes 
For the solution of the optimization problem both gradient-based and stochastic (GA) 
algorithms were investigated. Derivative-based algorithms generally offer much faster 
convergence when the objective function is smooth and convex or with relatively small 
number of local optima. When this is not the case however, stochastic methods are more 
appropriate, since such methods are more robust to poor initial guesses. A numerical 
analysis was performed to investigate the nature of the optimization problem to 
understand why the GA appeared to be more appropriate. To do this, we performed brute-
force evaluation over the antisolvent profiles of i  and   for two injections, and 
plotted the responses. The crystallizer modeled using this approach used all the same 
parameters as in Alvarez and Myerson[169].  Missing sections of these plots denote an 





Figure 4.2 L43 and  response surfaces for two injections. The landscapes (a) and (b) 
present nonconvexity that makes gradient optimization difficult. Great sensitivity to 
antisolvent flowrate is observed. The contour plots (c) and (d) are zoomed closer to the 




Figure 4.2 shows the response surface for two injections. The nonconvexity we believe is 




growth-dominant regimes along the length of the array. We further remark that the 
objective landscape appears highly sensitive around some of the extreme points. The 
maximum i (80.2 µm, black arrow, Figure 4.2c), rests at the crest of a tall, knife-like 
ridge. This indicates that the optimal  is highly sensitive to model or implementation 
uncertainties. Small deviation in flow rate A2 would greatly reduce the mean size of the 
actually obtained CSD. Furthermore, deviations in the crystallization kinetic parameters 
from the nominal values are also likely to lead to large deviations from the theoretically 
optimal performance. An analogous problem exists in the  landscape, where we can 
see that global minimum and global maximum are in close proximity. The  global 
minimum (0.195, white text, Figure 4.2d) lies in a narrow valley behind the sharp crest 
containing the  global maximum (0.351, black arrow, Figure 4.2d). Any error in A2 





4.5.2 Multi-Objective Optimization Results 
In this section, different sets of kinetic parameters are used to generate the Pareto 
frontiers calculated by the NSGA-II algorithm. The motivation for analyzing this 
sensitivity lies in the fact that there can be appreciable uncertainty involved in the 
estimation of the kinetic parameters and as such it is a good idea to investigate the impact 
of these uncertainties on the crystallizer performance. These results are for a four-
injection PFC array, with the same dimensions and flowrates as given by Alvarez and 




obtained results are shown in Figure 4, where the default case is for 9 = 7 = 1 . 
Altering the kinetic parameters (89 and 87) by ±50% affected the position of the Pareto 
front. The results indicate small sensitivity in the realized CV, though  shows higher 
sensitivity. The genetic algorithm used a population size of 100, and was permitted to run 
for a maximum of 500 generations, though on average finished after about 165 
generations. In summary, for about 50% error in the kinetic parameters manipulated, little 
change can be observed in , and i varies by about ±2.5 µm, which is also relatively 
small, indicating that the conclusions of the approach are relatively robust to variations in 
the model parameters. We wish to emphasize here that the parameters were manipulated 
prior to optimization, and thus these results indicate the sensitivity of the optimization to 








Figure 4.3 Pareto frontier plots for four injections (  vs. L43) and different sets of 
kinetic rate parameters, kb and kg. The ’s in the legend correspond to multipliers of the 
base case, e.g. γb = kb’/ kb. The base case corresponds to γb = 1 and γg = 1, with kb = 1.3 x 
10
8 #/(m3·s), and kg = 9.9 x 10
-7 m/s. We observe that there is some sensitivity with 
respect to these parameters on the Pareto frontier, but mainly the effect appears in L43. 
Little shift is seen in the realized coefficients of variation. For clarity, only the final 25 




4.5.3 Investigation Into the Sensitivity to Kinetic Parameters 
In the reverse case, we have chosen a representative point from Figure 4.3 (the black 
arrow), and varied the kinetic parameters by ±50%  after the optimization has been 
performed (Figure 4.4). This gives us an idea of how sensitive the solutions themselves 
are to error in the kinetic parameters. As expected,  increases with the increase of 87 
and decreases with the increase of 89. Counter-intuitively, we see that  decreases as 
89increases. We expected higher nucleation produce more fine crystals, thus increasing 
. To determine why this is, the finite-volume solver was used to plot the volume 




































γb = 0.5, γg = 0.5
γb = 1.0, γg = 0.5
γb = 0.5, γg = 1.0
γb = 1.0, γg = 1.0
γb = 1.0, γg = 1.5
γb = 1.5, γg = 1.0




fraction distributions of crystals at the three numerical labels in Figure 4.4b. These 
distributions are shown in Figure 4.5. It is observed that the mean size does indeed 
decrease with increasing 89. However,  slightly decreases due to the elimination of the 
second mode (the smaller hump in the blue curve in Figure 4.5). It appears that a higher 
89 reduces the ability of growth processes to spread out the distribution. This is because a 
total antisolvent of 200 ml/min was used, thus “locking in” the total available 
supersaturation. Higher nucleation consumes more of this available supersaturation, 
leaving less available for growth. Thus we see a narrowing of the distribution due to 






Figure 4.4: Variation in L43 and CV for the representative chosen point. Significant 





Figure 4.5: Volume size distributions of crystals as a function of nucleation rate constant, 
kb. It is observed that increasing kb decreases the mean size (approximately the mode), but 
shape-wise the peaks are isomorphic. The second mode in the blue curve is eliminated 




4.5.4 Comparison between Heuristic Antisolvent Profiles and Rigorous Optimization 
Alvarez and Myerson [169] experimented with splitting 200 ml/min antisolvent equally 
over 1, 2, 3, and 4 injection points in the PFC array, and observed the effect on the 
volume size distribution. We show that rigorous optimization of antisolvent profile 
predicts a better result. Referring to the black arrow in Figure 4.3, we have selected a 
representative point from the Pareto front of the nominal case ( = 89.98 µm,  = 
0.20), which uses the original set of kinetic parameters (89 = 1.3 × 10© #/(m3·s), and 




cases are given in Table 6. Plugging these profiles into the finite-volume solver generates 





Figure 4.6: Volume fraction distributions of crystals for 1, 2, 3, and 4 equal-flow 
injections, and the optimal 4-injection profile of the antisolvent. In the 1, 2, 3, and 4 
injection plots, 200 ml/min of antisolvent is split equally a corresponding number of ways 
among the injections. The optimal result uses the flows taken from the representative 




The corresponding antisolvent profiles are listed in Table 2. The optimization has left CV 
essentially the same, but has substantially increased . The optimal profile is different 




that at the first segment about 30% of the total antisolvent is added which generates 
enough supersaturation so that nucleation occurs. At the second segment almost no 
antisolvent is added so that the crystals from the first segment can grow in moderate 
supersaturation without further nucleation. In the subsequent two segments the remaining 





Table 6 Antisolvent flow profiles used to generate the crystal volume size distributions 
shown in Figure 4.6 and the corresponding performance index. 
Cases 
Flow in injection port (ml/min) 
Performance 
index 




1 200 × × × 64.47 0.21 
2 100 100 × × 70.8 0.21 
3 66.7 66.7 66.7 × 83.25 0.21 
4 50 50 50 50 70.35 0.21 







It is interesting to note that the 4 equal injections case in Figure 4.6 is inferior to the 3 
equal injections case, which disrupts the trend demonstrated from the  sizes produced 
from the preceding three cases. To understand the cause of this, observe the plot of 
concentration versus external length in Figure 4.7. It can be seen that in the 4-injection 
case, the operating point after the first injection is in the first segment is below the 
solubility curve, and thus the antisolvent addition generates no supersaturation, hence the 
first segment having no contribution to the crystallization process. In the second segment 
the crystallization is operated in the metastable zone, but without the first segment the 
total residence time available for the crystal growth after crystals can form is shorter than 
in the other cases, therefore crystals cannot grow to larger sizes. Since during antisolvent 
addition, the concentration in the system decreases due to the dilution effect 
simultaneously with the decrease in solubility, this dilution effect has to be taken into 
account to make sure that enough antisolvent is added in the system to reach 
supersaturation. In the case of the 3 equal injections, the first PFC segment already 
operates in the metastable zone, yielding nucleation and then growth in the rest of the 
length of the PFC. In the optimal case, it appears the best procedure is to generate a 
moderate supersaturation initially, and then quickly reduce it to a lower level. The likely 
interpretation of this result is that initially supersaturation is desired to be relatively high, 
encouraging nucleation as soon as possible so that there will be enough residence time for 
growth. Once sufficient crystals have been generated, lower supersaturation would then 
foster growth. The single addition generates very high supersaturation immediately 
promoting excessive nucleation in the system, whereas the two equal injection generates 




case, following a relatively similar operating curve in the phase diagram. This is in 
correlation with the results in Figure 4.6, which show that the final CSDs are similar for 





Figure 4.7 Concentration vs. external length plot for equal splits of total antisolvent 
across one, two, three, or four sections. The optimal result from the representative point is 








4.5.5 Investigation of Design Robustness with Regards to Antisolvent Flowrate Error 
In optimization and control practice optimal solutions are often sensitive to parametric 
and/or control variable uncertainty. It is important to know the robustness limits 
especially for equipment with the production of pharmaceuticals in mind, as designs with 
high variability are counterproductive to implementing QbD. In this section, we have 
investigated the sensitivity of the previous optimal profile to uncertainty in the 
antisolvent flow profile. We are especially interested in flow profile robustness, since the 
results in Figure 4.2 suggest there is great sensitivity to error in antisolvent flowrates. 
Error was simulated in the process by a simple Monte-Carlo simulation. Using the same 
optimal flow profile from Table II, random samples were taken from the nominal values 












1 59.90 29.95 89.85 
2 1.22 0.61 1.83 
3 57.72 28.86 86.58 






The first robustness simulation only permitted error in a single segment in the entire 
apparatus. 104 trials each were done for each of the four flowrates. After a random flow 
vector was chosen, the MOM solver was used to solve for  and , and the results 
presented as scatterplots. The results for varying a single flowrate are shown in Figure 4.8 
below. The red dot corresponds to the nominal (zero-error) case. Figure 4.8 clearly shows 
that uncertainty of flow in the first stage has the most impact on the process. The 
scatterplot has traced out a wide envelope of points that resemble a continuous curve. The 
uncertainty in subsequent flows is ineffectual, as the scatter plot of points have all hardly 









Figure 4.8 Robustness analyses with respect to flowrate by varying a single flowrate. The 
Roman numerals correspond to the particular MSMA-PFC segment for which random 
antisolvent flows are being sampled by the simulation. The red dot is the result for the 




We further examined the effect of error in multiple simultaneous stages, by permitting the 
same level of variation, but also varying the stages cumulatively. Figure 4.9 below shows 





Figure 4.9 Robustness analyses for multiple varying flowrates. The Roman numerals 
refer to which stage, and all others preceding it, are being sampled by the simulation. The 




Stage II imparts only mild change in the response, which is likely due to the small 
flowrate. However, significant variation is observed when stage III is reached, and many 
new points are reachable that are not present in Figure 4.8. Figure 4.9 suggests that the 
first stage, where primary nucleation occurs, is by far the most sensitive segment. 
Furthermore, the increase in nucleation in stage III also makes the process sensitive to the 







4.6 Summary and Conclusions Regarding Flufenamic Acid Optimization Work 
The chapter describes a multi-segment multi-addition continuous plug flow antisolvent 
crystallization (MSMA-PFC) setup. We utilized an integrated simulation and 
optimization framework to analyze the performance and robustness of the MSMA-PFC. 
The population balance model of the MSMA-PFC was introduced, which was solved, 
depending on circumstance, with either the method of moments, or the finite-volume 
method. The model was used in a model-based multi-objective optimization framework 
to design optimal antisolvent addition policies that maximize mean size and minimize 
coefficient of variation, using a genetic algorithm for global optimization and to compute 
the Pareto frontiers, which were also analyzed in the case of uncertainties in the model 
parameters. Concerning the robustness analysis of the antisolvent flowrates, it appears the 
proper control of nucleation will have significant process impact, and that uncertainty in 
antisolvent flowrate will drastically affect performance wherever nucleation 
predominates over crystal growth. We also conclude that error is best treated by 
considering the flow profile as a whole, since there appears to be significant interaction 
between how the upstream stage impacts the downstream performance – a known issue in 




CHAPTER 5. SIMULTANEOUS DESIGN AND CONTROL OF THE MSMA-PFC 
5.1 Abstract 
We have investigated the simultaneous design and control (SDC) of the MSMA-PFC. 
The SDC framework allows us to optimize not only over flowrates, but over the 
crystallizer geometry as well. By use of rigorous modeling and optimization, we solve a 
combined design and control problem to find superior crystallizer designs with 
corresponding optimal operating conditions for the MSMA-PFC. The procedure works 
by optimizing the MSMA-PFC crystallizer for various 2-tuples of total length and 
number of injections. In the first part of this study, we revisit the flufenamic acid 
optimization discussed in CHAPTER 4. The results indicate greater mean crystal sizes 
are attainable using the SDC approach. We then repeat this same analysis, but now also 
have feed flowrate and total antisolvent flowrate as decision variables. For both cases we 
examine the results derived by either maximizing the mass-mean crystal size, or 
minimizing the coefficient of variation. The results are plotted as landscapes with the 
number of injections and the total length as the independent variables. When feed and 
total antisolvent flowrate are used as decision variables, generally higher feed flowrates 
are observed when minimizing . There is little difference between the landscapes of 
total antisolvent addition. The residence time landscapes show that the optimal residence 




injections. Plots of the crystal size distributions show that minimization of  leads to a 
much smoother crystal size distribution, albeit with much lower mean size. We 
investigated in greater depth the maximum case of 25 injections. Here, maximization of 
  leads to more complicated multimodal distributions. This is likely due to the 
calculation of  being heavily biased towards larger crystal sizes. When total flowrates 
are used as decision variables, the antisolvent addition profiles for the two cases do not 
exhibit any distinct patterns or cycling action as was seen previously when they were not 
used as decision variables. Antisolvent addition is always widely distributed across the 
length of the crystallizer, indicating that better results are obtained by lengthwise-
distribution versus using a single addition at the beginning of a single tube. Adjustment 
of total length does not reveal any patterns in the antisolvent addition profiles. The 
growth and nucleation rate profiles show that most of the growth and nucleation take 
place in the first half of the crystallizer, and that nucleation and growth rates decline 
toward the end. There is significant differences between the growth and nucleation rate 




5.2 Simultaneous Design and Control (SDC) Framework for the MSMA-PFC with 
Static Feed Flowrate and Static Total Antisolvent Flowrate  
We examined a new type of optimization problem for the MSMA-PFC, in terms of not 
only the antisolvent profile, but the number of injections and the total crystallizer length 




that aims to provide the best MSMA-PFC design which can provide the overall best 
performance under optimal operating conditions. This problem leads to a more 
complicated mixed-integer nonlinear programming problem (MINLP) [193], [194], since 
the decision variables consist of a set of discrete variables (total length and number of 
injections), as well as a set of continuous variables (the individual antisolvent flowrates). 
The complexity of the SDC problem necessitates a single-objective approach. Figure 5.1 
presents a flowchart that explains the method used, with the following steps:  
1. To optimize the PFC array, an initial total length was assumed, @. 
2. As shown in (4.4), this length is cut into progressively smaller fractional sub-
segments of equal length. Antisolvent is injected at the beginning of each 
segment, just like in (4.4). 
3. For each of these injection sub-cases, the single-objective genetic algorithm 
manipulates the antisolvent flowrates into each segment in order to either 
maximize the  crystal size at the exit, or minimize  at exit. 
4. After a maximum number of injections are iterated over (15 in this case), @º»º¼½ 
is increased, and the process begins anew. 
5. The loop continues until the last injection the final @  is reached. The 
outputs of these optimizations generate landscapes of , , and yield. 
 
Yield was calculated according to the equation: 





  The MOM was used to speed up the solution of the model equations called by the 
genetic algorithm. Total antisolvent flow was constrained to be equal to 200 ml/min (the 
original value from CHAPTER 4), and the decision variables used by the GA were 
percentages of this amount (constrained to sum to 100%). The feed flowrate was kept 
static at 100 ml/min (again, the same value used in CHAPTER 4). An initial population 
of percentages was used for each start of the genetic algorithm, drawn randomly and 
made to satisfy this constraint. The population size scaled up with the problem size 
according to 100 + 25 , where   is the number of injections for the current problem 
being solved by the GA. A maximum of 200 generations was used. All other solubility 
and kinetic parameters were kept the same as in Alvarez and Myerson[169]. At the 
conclusion of the optimization, the icrystal size, , and yield were calculated and 
stored for later plotting. The total length began at 10 meters, and was increased in 10 
meter increments to 50 meters. The number of injections began at 2, and was increased in 





Figure 5.1 Flowchart for the simultaneous design and control (SDC) optimization of the 
MSMA-PFC array. The algorithm proceeds by cutting a PFC array of a given total length 





5.3 Results for Simultaneous Design and Control (SDC) Optimization with Feed 
Flowrate and Antisolvent Flowrate Kept Static 
5.3.1 Landscape Plots of Total Length vs. Number of Injections 
Figure 5.2 shows the results for the simultaneous design and control (SDC) optimization 
of the entire MSMA-PFC array. Generally, as expected we observe larger crystal sizes 
with increasing total crystallizer length, due to longer residence time. The number of 
injections does not appear to make much difference in   past about 5 injections. 
However, in Figure 5.2b, increasing the number of injections tends to reduce  further. 





































value of about 93%. This result stems from the fact that the total flow of antisolvent is 





(a) (b) (c) 
Figure 5.2: Results of the simultaneous design and control (SDC) optimization 
framework for the MSMA-PFC array over length, number of injections, and antisolvent 
profile, showing (a) the L43 crystal size, (b) coefficient of variation (CV), and (c) the solid 




5.3.2 Further Investigation of the Maximum Obtained L43 and Minimum Obtained CV 
The maximum obtained  size was 135 µm at @ = i50 meters and 11 injections. 
The  for that point was 0.24. The minimum  was 0.207, obtained at @ = i20 




greater detail in Figure 5.3. Figure 5.3a shows the volume CSD’s for these two points. 
We can see the multimodal nature in the '> distribution, which is indicative of some 
cyclic behavior in the process. This behavior is not present in the '0  volume 
distribution. The explanation for this is seen in Figure 5.3b, which shows the antisolvent 
profiles. We can see the optimal profile for maximizing   produces a cyclic-type 
“bursting” of antisolvent. Physically, we interpret this as the optimization seeking to 
avoid unnecessary nucleation, and focus on growing a smaller number of crystals that 
were nucleated near the beginnings. On the other hand, the '0  antisolvent profile 
indicates that most of the antisolvent is added in the second half to minimize variation in 
the size. In the former case the operation is characterized by a more aggressive nucleation 
generation in the initial part of the crystallizer to favor the formation of crystals as soon 
as possible maximizing the residence time available for growth, whereas in the latter the 
minimization of the   requires more gentle nucleation control at the beginning to 
minimize the multi-modal nature of the CSD, and then gradual increase of the 
supersaturation. The results indicate that for optimal performance equipment should be 
designed to allow the implementation of the appropriate optimal control strategy 
depending on the objectives. Future continuous crystallizers therefore need to be 
designed to be flexible, reconfigurable and adaptable to allow optimal operation. This can 






Figure 5.3: Results for SDC over total length, number of injections, and antisolvent 
profile. We have chosen two points from the surfaces in Figure 5.2 for examination – one 
point corresponding to the maximum obtained L43, and the other corresponding to the 
minimum obtained . (a) shows the volume CSD’s for these two points. The antisolvent 




5.4 Problem Formulation for Case When Total Flowrates are Used as Decision 
Variables 
In the prior results discussed in section 5.3, we used a fixed total antisolvent flowrate and 
a fixed feed volumetric flowrate. In the results in this section, these strictures have been 
removed and total antisolvent (, ml/min) and feed flowrate (##%, ml/min) have 
become bounded decision variables. Much like in section 5.3, we have investigated how 
the results change whether the objective is to maximize   or the minimize  . 




MSMA-PFC length and the number of injections. The model equations, parameters, and 
solution methods are identical to those in CHAPTER 4. The two optimization problems 
solved independently (not multi-objective) were: 
i .@ .! , ##%,   
(5.2) 
and 
i : .! , ##%,   
(5.3) 
Both of which were subject to: 
i






0 − 1.050 ≤ 0 
−0 + 0 ≤ 0 
(5.4) 
The prior SDC results did not require a yield constraint, as using a fixed quantity of 200 
ml/min antisolvent with 100 ml/min of feed would “lock-in” the final yield. However, 
with ##% and  now free decision variables, a constraint on yield is now require to 




5.5 Results and Discussion for Case When Antisolvent Flowrate and Feed Flowrate are 
Decision Variables 
5.5.1 Landscapes for Feed Flowrate 
  
(a) (b) 
Figure 5.4 Optimized landscapes of feed volumetric flowrates (Vfeed) against total length 
of PFC array and number of PFC injections. In (a) the objective was to maximize L43. In 




The results in Figure 5.4 are the optimal values of ##% for various ordered pairs of total 
length and numbers of injections. In this section and all of the succeeding sections in this 
chapter, all data corresponding to the maximization of L is presented in red, and all data 
corresponding to the minimization of CV  is presented in blue. While these data are 
somewhat noisy due to the use of the GA, some trends can be noticed. First, we observe 




suggesting longer arrays with more injections can handle a higher mass throughput. We 




5.5.2 Landscapes for Total Antisolvent Flowrate 
  
(a) (b) 
Figure 5.5 Optimized landscapes of total antisolvent volumetric flowrates (Atotal) against 
total length of PFC array and number of PFC injections. In (a) the objective was to 




Figure 5.5 shows the optimal values of  for the two optimization problems. These 
results however, are much closer to one another than the previous plot. A general trend 




similarity in shape may be due to the fact that both optimizations are subjected to the 
same yield constraint. Thus, a higher feed flowrate would demand a higher antisolvent 
flowrate in order to deplete the supersaturation to within feasibility. This suggests that the 




5.5.3 Landscapes for Residence Time 
  
(a) (b) 
Figure 5.6 Optimized landscapes of residence time () against total length of PFC array 
and number of PFC injections. In (a) the objective was to maximize L43. In (b) the 




Figure 5.6 shows the residence time landscapes. We can conclude than that optimal 




independent of the number of injections. The similarity between the two plots suggests 
that total residence time is not precisely what differentiates the two control strategies 
arrived at by the optimization, and that the individual flowrates are much more important. 
The relative independence of residence time with the number of injections suggests that 
the optimal residence time is determined more by the yield constraint and tube geometry, 




5.5.4 Landscapes for Mass-Mean Crystal Size and Coefficient of Variation 
  
(a) (b) 
Figure 5.7 Optimized landscapes of mass-mean crystal size (L43) against total length of 
PFC array and number of PFC injections. In (a) the objective was to maximize L43. In (b) 
the objective was to minimize . 
 
Figure 5.7 shows the landscapes for mass-mean crystal size. Clearly, maximizing  




with the Pareto frontier results from section 4.5.2, which show that there is a significant 
tradeoff between these two quantities during optimization. We furthermore note that there 
is not much increase in the maximum obtained crystal size (about 140 µm) compared to 
the 135 µm in Figure 5.3. The landscapes for coefficient of variation are shown in Figure 
5.8 below are somewhat puzzling in that the results in Figure 5.8a show generally lower 
  than those in Figure 5.8b. This may be due to the greater complexity of the  
objective function causing improper convergence, as evidence by the landscape plot in 
section 4.5.1. However, certain points do show significantly higher   when solely 
attempting to minimize , suggesting again that a more aggressive crystallization leads 











Figure 5.8 Optimized landscapes of coefficient of variation () against total length of 
PFC array and number of PFC injections. In (a) the objective was to maximize L43. In (b) 




5.5.5 Number Fraction Distributions for the Case of 25 Injections 
Figure 5.9 shows the final exit distributions calculate using the finite-volume method for 
the case of 25 injections for the crystallizer lengths of 1 meter and 50 meters. The two 
distributions in each graph correspond to either attempting to maximize , or minimize 
. We can see in Figure 5.9 two main features that stand out from this data. Maximizing 
 tends to lead to a multimodal distribution (Figure 5.9a red curve). This is because the 
objective was to maximize  , and   the calculation of   is dominated by larger 




not tend to be multi-modal. We observe though the longest tube length of 50 meters, the 





Figure 5.9 Number fraction distributions for the case of 25 injections. Each plot 






5.5.6 Antisolvent Profiles for the Case of 25 Injections 
(a) (b) 
Figure 5.10 Antisolvent fraction profiles for the case of 25 injections. Each plot 




Figure 5.10 above shows the antisolvent fraction profiles for the two optimization cases. 
Generally, it is difficult to discern noticeable features from these profiles, indicating that 
optimal or near-optimal solutions are not intuitive. Nearly all addition used less than 10% 
of the total antisolvent. The profiles are different from each other, agreeing with intuition 
that total length is a significant design variable that directly impacts the optimal possible 





























































5.5.7 Growth and Nucleation Profiles for the Case of 25-Injections 
Figure 5.11 shows growth and nucleation rate profiles for the case of 1 meter and 50 
meters total length when maximizing the mean crystal size. Figure 5.12 likewise shows 
the same type of figures for those same lengths, but for the case of minimizing the 





Figure 5.11 Growth and nucleation rate profiles for the case of maximizing mass-mean 
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Figure 5.12 Growth and nucleation rate profiles for the case of minimizing coefficient of 




For the case of maximizing mean size, generally, the optimization seeks to raise the 
growth and nucleation rates in a pulsing fashion. However, two of the plots show 
exception to this rule. Figure 5.12a shows a distinct “jagged hill” type profile which is 
not seen in any of the other plots. It is also worth noting that this profile scored a much 
lower  than was typical (about 0.08) in Figure 5.8b. This suggests that many small 
segments are required to exert effective control over the fast-acting process of nucleation. 
Figure 5.12b shows that virtually all of the growth and nucleation occur in the first stage 
as a crash crystallization. Intuitively, growth and nucleation decline toward the end of the 
crystallizer. This is partly in order to satisfy the yield constraint, but also because 
available supersaturation is being consumed by growth and nucleation. 
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5.6 Summary and Conclusions 
A simultaneous design and control (SDC) framework is proposed based on the complete 
optimization of the entire PFC array over total length, number of injections, feed flowrate, 
total antisolvent flowrate, and antisolvent profile. It is shown that, for the case of static 
feed and antisolvent flowrates, the typical optimal antisolvent addition protocol leads to a 
cyclic operation which promotes shifts between growth-dominated and nucleation-
dominated regimes in the different PFC segments. This periodic operation yields to a 
strongly nonconvex search landscape motivating the use of genetic algorithm for the 
optimization. We have also investigated the performance of the MSMA-PFC when feed 
flowrate and total antisolvent flowrate are used as decision variables as well. The results 
indicate that there is little increase in maximum  crystal size compared to the results in 
CHAPTER 4, though significantly lower CV’s can be obtained. However, higher 
flowrates are obtained by the optimization, indicating a higher mass flowrate can be used 
without reducing the mean size. The flow profiles have no discernible pattern, but do 
indicate that there is benefit to distributing antisolvent across the length of the crystallizer. 
The growth and nucleation rate profile plots indicate, for both optimizations, a general 
pattern of high supersaturation at the beginning of the crystallizer, with supersaturation 
being “pulsed” down the remainder of the length of the crystallizer. The SDC framework 
can be used to design flexible, reconfigurable and adaptive continuous crystallization 
systems that can achieve optimal performance by allowing the implementation of the best 




CHAPTER 6. PARAMETRIC STUDY OF THE FEASIBILITY OF IN-SITU FINES 
DISSOLUTION IN THE MSMA-PFC 
6.1 Abstract 
We have investigated the use of an antisolvent MSMA-PFC , which can grow and keep 
extant large crystals while dissolving fines in-situ. By applying and extending the 
framework discussed in CHAPTER 5, we have shown that dissolution is rejected by the 
optimization and that dissolution is suboptimal. A reduced orthogonal array experimental 
design was used to avoid a high computation time. The results of the main-factor analysis 
show that nucleation rate imparts the greatest process sensitivity, followed by growth rate. 
High nucleation overwhelms the MSMA-PFC. The MSMA-PFC performs best under 
kinetic crystallization conditions in which a single PFC also works sufficiently well, 





While purification is the main motive behind crystallization, the crystal size distribution 
(CSD) affects downstream operations and the ameliorative properties of the final dosage 
form. Downstream processes affected by CSD shape include filtering, washing, and 




The curative properties of the final dosage form are dependent on the dissolution rate and 
bioavailability, which are strongly affected by the CSD and other particle properties 
[110], [195]. The typical method of removing fines is to classify the product crystals, re-
dissolve the fines, separate the antisolvent when feasible, and recycle the mixture back to 
the crystallization system. However, this method is problematic. Classification, recycle, 
and stream separation require further process equipment, increasing capital and operating 
costs. Classification combined with recycle has been mathematically deduced (and 
subsequently observed) to impart oscillatory dynamics to the CSD. These oscillations 
make it difficult to obtain a consistent product. Furthermore, from a risk analysis 
viewpoint, extra equipment is generally “more things that can go wrong”, and present 
another route by which microbes could contaminate the manufacturing process. Ideally, it 




6.3 Prior Work on In-Situ Fines Removal 
Previous work by Abu Bakar et al. [195] and Majumder and Nagy [113] explored the 
concept of “in-situ” fines removal, where the operation of the crystallizer actively 
eliminates fine crystals during the crystallization by means of dissolution. With this 
approach, classification, re-dissolving, and stream separation become (in theory) 
unnecessary. The work by Majumder and Nagy [113] most closely follows our work here. 
In that work, a constrained nonlinear optimization problem was solved to identify 




removing fine crystals. Majumder and Nagy [113] previously investigated 
computationally the use of multisegment cooling crystallization for in-situ fines 
dissolution. In that work, the decision variables were the jacket temperatures in each 
segment, which allowed the particular segment to go above or below solubility as 
necessary to dissolve the fine crystals and grow large ones. Ridder et al. [161], [162] have 
modeled and optimized a multi-segment antisolvent crystallizer for drug crystal 
production, but that work did not allow for dissolution to occur. This work is an 
extension of the previous works by Ridder et al. and Majumder and Nagy, as we are now 
using an antisolvent crystallization with the capability to dissolve crystals when below 
solubility. Figure 6.1 below depicts the path of information flow for a cooling PFC 
crystallization process, and an antisolvent PFC crystallization process. For an antisolvent 
crystallization, the decision variables are the flowrates of antisolvent into each segment. 
The cooling crystallization has no coupling between residence time and the control 
(jacket temperature), and residence time is constant within each segment. None of this is 
true in antisolvent crystallization, since the addition of antisolvent simultaneously affects 
the current concentration via dilution, and reduces the current residence time due to a 










Figure 6.1 Information flow diagrams in a multisegment crystallizer for (a) cooling 




6.4 Parametric Study via Optimization of the Antisolvent Crystallizer 
In this work, we present results for the steady-state operation of a multi-segment, multi-
addition, plug-flow crystallizer  MSMA-PFC which utilizes dissolution to eliminate fine 
crystals. We have explored the geometric design parameters of the crystallizer, as well as 
the kinetic parameters of crystallization. To reiterate, this work is an extension of that by 
Majumder and Nagy [113], but for the case of antisolvent crystallization as opposed to a 







6.5 Model Framework 
 
Figure 6.2 Diagram of the MSMA-PFC. Seeded liquid solvent, with solute concentration 
C0 flows in from the left into a mixing chamber (gray box). The dilution correction factor, 
γj, is applied to the exit stream around each mixing point (red dashed boxes). The 
combined streams then flow into a plug-flow segment (blue rectangle). Antisolvent 
reduces solubility, triggering nucleation and growth. Streams of pure solvent are utilized 




The model presented here is similar to that discussed in CHAPTER 4 and CHAPTER 5. 
Some important differences we mention immediately are: 
• The greatest difference is that the model now accepts pure solvent additions in 
addition to antisolvent. The addition of pure solvent can permit the crystallization 
to go below solubility, thus inducing dissolution of the crystals. The idea is to 
dissolve the smallest crystals, while keeping the large ones relatively intact. 
• Before, ethanol was the solvent and water the antisolvent. In this chapter, water is 
the solvent and ethanol is the antisolvent. 
• Flufenamic acid was the solute in the first model, whereas here we have no drug 



























































• In the prior model, concentration and number density were expressed on a volume 
of solution basis. In this chapter, concentration and number density are based on a 
mass of solution basis. 
• The prior model was unseeded, with primary nucleation present. Here we are 
using a seeded process with secondary nucleation present. 
The MSMA-PFC is based on the setup in Alvarez and Myerson [135]. It is modeled as a 
series of ideal plug flow elements, of equal length, and antisolvent is added at the 
beginning of each segment (Figure 6.2 above). Each of the N segments is a separate PFC, 
running in steady-state, isothermal operation. The inlet stream (far left) feeds saturated 
mother liquor at flowrate ##% (ml/min), with an initial concentration of solute,  (kg 
API/kg solution), and a seed CSD, : (# of crystals/kg of solution∙m). At each mixing 
point (gray boxes in Figure 6.2), antisolvent flowing at flowrate ! (ml/min), and pure 
solvent at flowrate  ! (ml/min), for  = 1,2, … ,. We reiterate that we are using mass-
intensive units for our state variables, : (#/kg solution) and  (kg API/kg solution). After 
mixing with the solvent and antisolvent streams, the mixture then flows into the J PFC 
segment, where nucleation and growth occur. We assume the streams mix on a time scale 
well below the induction time, and also attain plug-flow. At the exit of the segment, a 
new size distribution, :(, @!#0%) , and a reduced solute concentration, (@!#0%) , are 
obtained. We will abbreviate these quantities as :!#0% and !#0%. We clarify to the reader 
that this is not the same as !£H or :!£H; these quantities are created when the next solvent 
and antisolvent streams are added; the pattern of indexing is made clear in Figure 6.2 




Ji segment (product stream). The final crystal size distribution, :#0% , is used for 
solving the least-squares optimization problem. Both :#0% and #0% are used to calculate 
several constraints. Summation indices always use the letter  as a dummy index. The 
letter  always refers to “for the J  PFC segment.” When an index refers to a mixing 
point,  always refers to the mixing point immediately preceeding the J PFC segment 
(e.g. thei = 1 mixing point is the very first mixing point on the left hand side in Figure 
6.2 above). 
 
The addition of streams !  and  !  to the process causes a decrease in   and :  in the 
oncoming feed stream due to the effect of dilution. Concentration and number density are 
reduced is because the solute mass (and crystal mass) has remained the same, but total 
volume has increased. There is a double meaning of this term in the literature, as some 
authors refer to antisolvent crystallization as “dilution” [51]. We reiterate that in this 
paper, we refer to dilution as being the reduction in solute concentration due to the 
addition of liquid. To account for this effect, the number density of the J  outgoing 






Where K!0 is the density of the solution, and ! is the volumetric flow rate of the 
entire stream. ! can be determined by dividing the total solution mass flow rate by the 




 !£H0 =iKÁÂÃ##% +   
!H  + KÄÃÁ  !H iK!£H0  (6.2) 
Where KÁÂÃ  and KÄÃÁ  are the densities of water and ethanol (997 kg/m3 and 785.22 
kg/m3, respectively). The total solution density, K!£H0  (kg/m3), is calculated 
numerically from a curve fit of the density of an ethanol-water mixture in terms of 
ethanol mass fraction. These expressions are derived by performing progressively wider 
mass balances about the mixing points and PFC segments. The method is more easily 
explained with a diagram (Figure 6.3 below). The colored boxes demonstrate the pattern 





Figure 6.3 Mass balance envelopes that are used to derive γ dilution correction factor. 




6.6 Crystal Population and Solute Mass Balance Equations 
In order to properly model the crystallization, two equations need to be solved 











The population balance equation is the same as (4.2). The mass balance on dissolved drug 
is given by: 
 
/!/@ = −
K&86=>,! (3PGf,! + ,!) (6.3) 
The term Gf  is the second moment of the crystal size distribution (m2 of crystals/kg 
solution).  is the solute concentration in the liquid phase (kg API/kg solution), K& is the 
density of crystalline API (assumed to be 1490 kg/m3),  is the minimum detectable 
crystal size (m),  is the nucleation rate (# of nucleated crystals/kg solution∙s), and 86 is 
the dimensionless crystal shape factor (t/6 for spheres) [196]. The units of the derivative 
reduce to (kg of crystals/kg solution∙m external coordinate). In a pure mathematical 
treatment,  would simply be set to zero; however, all instrumentation used in practice 
for experimentation and process control will have limits to observability. When the 
crystallization is below solubility, the mass balance becomes: 
 
/!/@ =
3K&86OGf,!=>,!  (6.4) 










6.6.1 Boundary Conditions 
For the first segment ( = 1), the boundary conditions for these equations are: 
 
:H(, @ = 0) = γH: 
:H( = 0, @) = ,H PHv  
H(@ = 0) = γH 
(6.5) 
Where : is the seed crystal size distribution,  is the nucleation rate (#/kg of solution∙s), 
and  is the initial solute concentration. In subsequent segments ( ≥ 2), the boundary 
conditions become: 
 
:!(, @ = 0) = γ!:!H#0% 
:!( = 0, @) = ,! P!v  
!(@ = 0) = γ!!H#0% 
(6.6) 
A Gaussian bell curve was used for : (#/kg of solution∙m) in all cases, with mean F##% 
(meters) and standard deviation L##% (meters) (we would normally use the Greek letters 
G and Æ for the mean and standard deviation, but these letters already correspond in this 
work to the moments of the crystal size distribution and the supersaturation): 
 :() = L##%Ç2t exp­−
( − F##%)f2L##%f ® (6.7) 
Where   is the total number density (# of crystals/kg solution).   can be 
interpreted in (6.7) as a constant that forces the seed distribution to agree with the 
specified seed mass loading, _  (%, dimensionless). The mass balance on the seed 
distribution is closed by solving the algebraic equation for  such that: 




Where G,  is the third moment of the seed distribution. Equation (6.8) is closed by 
manipulating , which is embedded in the integral term G,: 







6.6.2 Growth, Nucleation, and Dissolution Rate Laws 
The growth and nucleation laws are given by the equations (again, alli subscripts refer to 
the J segment): 
 
P! ! = 87 !7 
,! ! = 89Gf !9 
O! ! = −`87(1 −  !)% 
 ! = !(@)/,! 
(6.10) 
Where   is the supersaturation ratio, 87 is the growth rate constant, T is the growth rate 
order, 89  is the nucleation rate constant, S is the nucleation order, O is the dissolution 
rate, /  is the dissolution order, and   is the solubility concentration (kg API/kg 
solution). P is replaced by O in (6.3) for  < i1, and / = 1 always in this work. We use a 
modified version of the growth law for the dissolution rate law. The dissolution rate can 
be approximated by multiplying the modified version of the growth law by a constant 
` > 1, which adjusts for the fact that dissolution is typically much faster than growth. 




related to equations (4.2) and (6.3) are given in Table 8 below. These variables were all 




Table 8 Physical and chemical property data table used for modeling the antisolvent 
crystallization. 
Parameter Value 
Initial concentration,  [kg API/kg solution, 
always saturated] 
0.030935 
Shape factor, [-] π/6 
Solid API density, [kg/m3] 1490 
Dissolution acceleration, φ [-] 250 
Number of segments,  [-] 50 
Seed crystal mean size, F##% [µm] 50 




6.6.3 Calculation of API Solubility 
The solubility of the API in a water-ethanol (solvent-antisolvent) mixture was taken from 
the experimental data plot provided in Figure 2 of Luo et al. [196] for the case of the drug 
biapenem. Data points were extracted from the curve using the DataToGraph utility, and 
are given in Table 9 below [197]. Comparison with various curve fitting methods in 
MATLAB showed that linear interpolation provided the best fit. The data correspond to a 





Table 9 Solubility data for biapenem-water-ethanol system. 
Water Mass Fraction, Xw Csat x 10
3













The water mass fraction in the J PFC is computed by: 
 *ÁÂÃ! = KÁÂÃ##% + KÁÂÃ   
!H
KÁÂÃ##% + KÁÂÃ   !H + KÄÃÁ  !H  (6.11) 
Plugging *ÁÂÃ!  into the curve fit object created in MATLAB yields the solubility 




6.7 Solution of Model Equations 
A typical method used for solving equations (4.2)  and (6.3)  is to apply the method of 
moments (MOM), which reduces system to a set of coupled ordinary differential 
equations for the moments of the crystal size distribution. However, this method is 




solve these equations, we have utilized a high-resolution finite volume (FV) technique, 
which is the combination of the semi-discrete FV technique with the van Leer flux limiter 
[113], [173]. This method provides Ê(ℎf) accuracy where the solution is smooth, without 
the oscillations found in other methods. Details on the finite volume method are given in 




6.8 Optimization Problem Formulation 
Our goal is to eliminate the production of fine crystals by utilizing dissolution. The 
quality of the elimination is ascertained by measuring how closely the attained number 
fraction distribution leaving the J PFC (1,#0%) matches a theoretically-best growth-
only crystal size distribution, 1"7#. The target distribution is generated by simulating 
the crystallization with only one segment, with nucleation arbitrarily set to zero. With no 
nucleation, all solute depletion is solely due to crystal growth on the seeds, and no fine 
crystals are ever created. Thus, the target distribution is a hypothetical best-case scenario 
of pure growth achieved without nucleation. The closeness of matching can be expressed 
in a least-squares sense. By manipulation of the antisolvent and solvent flowrates in each 
segment (and other decision variables), we can make the fit between the model and the 
target distribution tighter. The population and mass balance equations are solved for each 
segment, and the output of one segment recursively becomes the input to the next 




stream. Population density and solute concentration are adjusted for the dilution induced 




6.8.1 Least-Squares Objective Function 
The final number fraction distribution, 1 , is used for formulating the least-squares 
problem: 
 




Where [ is the vector of decision variables (listed in Table 10), and 16,,#0% is the volume 
fraction size distribution at the exit of the crystallizer. It is computed by: 
 1,#0% = :
#0%
s :#0%r / (6.13) 
The index  in (6.12) refers to a particular crystal size bin, with Q total bins. Note that : 
integrates to : (the total number of crystals in the solution), while 1 integrates to 1. 
We use the number fraction distribution instead of the number density, since the addition 
of extra solvent and antisolvent causes dilution. In the previous work on cooling 
crystallization by Majumder and Nagy [113], the least-squares function was formulated 
in terms of volume density, :6. In that work, there is no dilution effect, whereas in this 
work the effect of dilution reduces :6 monotonically with each liquid addition. If :6 were 




volumetric flow rates are not the same. Using the volume fraction distribution, 16 , 




6.8.2 List of Decision Variables and Bound Constraints 
All 2 + 5 decision variables in these optimizations had bound constraints. Table 10 



























Feed flowrate of saturated 
solvent 
[ml/min] 0 300 
 Total flowrate of antisolvent [ml/min] 0 300 
  Total flowrate of pure solvent [ml/min] 0 150 
/00#" 
Inner diameter of crystallizer 
tube 
[m] 10 × 10 25 × 10 
_ Seed mass loading [%, -] 2% 7% 
.H, .f, … , . 
Antisolvent distribution 
fractions 
[-] 0 1 
<H, <f, … , < 
Pure solvent distribution 
fractions 




The optimization of the MSMA-PFC is known to be highly non-convex, as shown by the 
landscape plots in Ridder et al. [161]. Such problems are not amenable to gradient search, 
and so we have opted for a stochastic approach to circumvent the nonconvexity. The 
genetic algorithm is a popular tool for solving optimization problems with this difficulty. 




antisolvent and total pure solvent. The flowrate into a segment   is the J  fractional 
distribution variable multiplied by total flow allotment. 
 
! = .! 





6.8.3 Linear and Nonlinear Constraints 
There were no linear inequalities in this study. The only linear constraints in this work are 
two equalities, which require the apportionments of total liquid flows must each sum to 
unity. The remaining six constraints are nonlinear inequalities. Table 11 below 

















Table 11 Linear and nonlinear constraints for in-situ fines dissolution optimization. 






 Total fractions of added liquid flows must 








Ì Æ#0% − 1.05 ≤ 0 Final supersaturation is bracketed between 
0.85 and 1.05. 
Nonlinear 
Ì 0.85 − Æ#0% ≤ 0 
Ì±  − 3600 ≤ 0 
 
Total residence time under 3600 seconds (1 
hour). 
Ìe 0.30 − R ≤ 0 





We require residence times of under 1 hour. In the multiple-cooling segment PFC array, 




However, the addition of antisolvent and pure solvent to the liquor flow changes 





= t/00#"f (@/)4 µ
1





Where @/iis the length of a single segment. The J  summand in (6.15) is the 
residence time for the J segment, which is the segment’s volume divided by the total 
flow rate through that segment. The total residence time is found by summing over all  
individual residence times. Since each PFC volume is the same, it is taken out of the 
summation distributively. 
 
Drug API products are typically expensive, making wasted API a serious expense. We 
require a crystal yield of at least 30% to trim unwise crystallization strategies from 
consideration. Yield is calculated in the following manner: 
 R = ##%KÁÂÃ − (##%KÁÂÃ +  KÁÂÃ + KÄÃÁ)#0%##%KÁÂÃ  (6.16) 
If #0% = 0 , then all of the solute has been crystallized, and thus R = 1 . If no 
crystallization has occurred, the numerator will be zero, and thus R = 0. If seed crystals 
have been dissolved due to excessive dissolution, then R becomes negative. 
6.9 Solution of Least-Squares Problem by the Genetic Algorithm 
The GA is less efficient compared to gradient-based methods, such as sequential 




guess, and can become trapped in a sub-optimal local minimum [198], [199]. This is true 
when the objective function and/or constraints are non-convex. Stochastic methods, such 
as the GA or simulated annealing, are appropriate for nonconvex optimization. The 
problem was solved by manipulating the 2 + 5  decision variables with the genetic 
algorithm (GA). Each set of kinetic parameters and crystallizer lengths listed in Table 13 
were optimized over to minimize the sum of the squares in (6.12). The GA initial 
population was created by randomly sampling over the bounds given in Table 10 above. 
The number of injections could not be used as a decision variable, as MATLAB’s genetic 
algorithm cannot solve mixed-integer nonlinear programming (MINLP) problems that 
have any type of equality constraint. The number of injections used was 50, which gave a 
good tradeoff between curve fit and computation time. The population size was 750, 
repeated for 25 generations. The MATLAB integrator, depending on the particular run, 




6.10 Results and Discussion 
6.10.1 Experimental Design Array 
To investigate the crystallizer’s performance for various kinetic parameters, a reduced 
orthogonal array experimental design was used, with five factors, four levels, and 16 total 
runs. The five factors are the nucleation and growth parameters, and the total crystallizer 





Table 12 Table of the five factors and four levels used for examining parameter space. 
Level 
Nucleation rate 
constant, ÍÎ [#/m2∙s] 
Nucleation 













1 1 × 10e 1 1 × 10¨ 1 5 
2 1 × 10¨ 2 5 × 10¨ 1.333 10 
3 1 × 10© 3 1 × 10e 1.667 15 




A reduced design was used, since exhaustive search over 45 = 1024 different 
optimizations was computationally prohibitive. This experimental table is given in Table 
13 below. The orthogonal array table allows for a good sampling of the search space with 










Table 13 Experimental design table of factors and levels for the curve fit optimizations 
conducted. The numbers correspond to the level column in Table 12. The sum of the 
squares of the errors (SSE) and total amount of pure solvent added (Stotal) are given for 
each run. 
Run # ÍÎ Î Í\ \ 3ÏÐÏÑÒ SSE ÓÏÐÏÑÒ 
1 1 1 1 1 1 
2.67E+07 80 
2 1 2 2 2 2 
4.71E+06 0 
3 1 3 3 3 3 
1.25E+07 1 
4 1 4 4 4 4 
7.58E+05 1 
5 2 1 2 3 4 
5.62E+08 3 
6 2 2 1 4 3 
7.42E+08 0 
7 2 3 4 1 2 
2.25E+07 2 
8 2 4 3 2 1 
6.93E+07 0 
9 3 1 3 4 2 
2.22E+09 8 
10 3 2 4 3 1 
2.10E+08 2 
11 3 3 1 2 4 
6.08E+09 0 
12 3 4 2 1 3 
3.10E+09 9 
13 4 1 4 2 3 
3.41E+09 11 
14 4 2 3 1 4 
7.82E+09 24 
15 4 3 2 4 1 
8.28E+09 25 








Table 13 shows the experimental design matrix, as well as the resulting sum of the 




6.10.2 Volume Fraction Distributions for Optimized Cases 
The data in Table 13 show that run #1 gave the tightest curve fit (Figure 6.4). The reason 
for this tight curve fit is due to the system exhibiting low nucleation (the 89 level is at the 
lowest level). Also in Figure 6.4 we show the performance of a single segment with 
nucleation turned back on ( > 0). We can see there is little improvement observed 





Figure 6.4 Volume-fraction distribution for run #1. 










































Increasing values of 89  rapidly degrade the curve fit due to overwhelming nucleation. 
Run #11 is representative of runs which are nucleation-dominated. As shown in Figure 
6.5, there is a large amount of fines created, and the optimal result fails to hit the target 
distribution. While we have improved the volume fraction distribution over the single-
segment case by producing less fines at the exit, there is still a great deal of fines 
produced. The nucleation rate constant has the greatest effect upon the performance of 



















































6.10.3 Main-Factor Analysis 
The results in section 6.10.2 suggest to us that the best results, intuitively, are obtained 
when the system is growth-dominated. Main-factor analysis of the experimental matrix 
confirms this suspicion. Main-factor analysis is done by taking the average of all SSE for 
a given factor at the same level. For example, the average for the factor 89 at level 2 
would take the average SSE of runs 5, 6, 7, and 8. This process is repeated for all five 





Table 14 Level-wise averages of SSE for each corresponding level and factor pair. 
SSE ÍÎ Î Í\ \ 3ÏÐÏÑÒ 
L1 1.12E+07 1.56E+09 4.89E+09 2.74E+09 2.15E+09 
L2 3.49E+08 2.20E+09 2.99E+09 2.39E+09 3.74E+09 
L3 2.90E+09 3.60E+09 2.53E+09 3.38E+09 1.82E+09 




This analysis reveals to us what the most sensitive parameters are, and also what 
combination of levels will theoretically provide the best curve fit – which we 
hypothesized would be the growth-dominated case. We can see in Table 14 that the factor 
89 spans the widest range of SSE values over the level averages. We thus conclude that 




most sensitive parameter is 87. The optimal curve fit is projected to be the set of levels 
for which SSE is a minimum for each corresponding factor. These values are shown in 
boldface in Table 14 (they are the minimum values within each column). The main-factor 
analysis projects that the tightest curve fit will be observed at a 89 of level 1, a S of level 
1, a 87 of level 4, a T of level 2, and ani@ of level 3. We term this the “projected 
optimum.” Note that this set of factors and levels is not present in Table 13. Solving the 
optimization problem with this new set of parameters generates the volume fraction 
distributions in Figure 6.6, which had an SSE of 4.83 × 10± , which is less than the 





Figure 6.6 Optimal fit predicted by analysis of the orthogonal array design. 
 






























Target w/ B0 = 0





This result matches our intuition that the best result is obtained when nucleation is slow 
and growth is fast. However, this has the effect of “cancelling out” the benefits of using 
multiple injections, as we obtain a very tight fit to the curve anyways when using a single 
injection for this set of kinetic parameters. There was no discernible trend observed with 




6.10.4 No Dissolution is Used to Control Fines 
It is interesting (even if a bit disappointing) to observe that the optimization does not 
want to use dissolution to get rid of fine crystals. The total amount of pure solvent added 
during each optimization is given as the rightmost column in Table 13. Observe that little 
to no pure solvent is ever added to the system for the optimal curve fits (observe in Table 
10 that  is bounded on the left by zero). The supersaturation profiles (  vs. @ plots) 
show barely any dissolution occurring. The supersaturation profile for the “project 













Note how the supersaturation does not significantly (or at all) go below 1 anywhere in 
Figure 6.7. This indicates to us that the situations in which the curve fit is superior to the 
single-segment case (Figure 6.4 and Figure 6.5) is more likely due to the better control 
offered by using multiple segments (and thus having finer control over supersaturation), 
rather than making use of fines dissolution. The reason the optimization refuses to add 
pure solvent in significant amounts is due to the fact that adding pure solvent reduces the 
concentration (via dilution) and reduces available residence time (via equation (6.15)). 
Reduced concentration reduces the available supersaturation, and reducing the residence 
time reduces the time available for growth inside the MSMA-PFC. Thus, despite the 
potential for dissolving fines, the benefit of adding pure solvent does not counterbalance 
the other two negative phenomena. 


































6.11 Summary and Conclusions 
We have investigated the use of the MSMA-PFC, run in antisolvent mode, for the 
growing of crystals while dissolving fines in-situ. The model equations solved were the 
partial differential population balance equation and the integro-differential mass balance 
equation. The solution method used was the finite volume method, since the entire CSD 
was required to calculate the sum of the squared errors for the curve fit. The final CSD 
was compared to a target CSD generated by arbitrarily setting nucleation to zero. A 
reduced orthogonal array experimental design was used to examine the effect of several 
kinetic parameters and total crystallizer length. The genetic algorithm was used to 
optimize over the decision variables, with the parameters from the experimental design 
held constant. The results indicate that 89 is the most sensitive parameter, followed by 87. 
As 89  increases, the curve fit degrades rapidly due to becoming overwhelmed by 
nucleation. Examination of the supersaturation profiles shows that dissolution is not 
occurring appreciably for any of the optimizations performed. The MSMA-PFC performs 
best under kinetic crystallization conditions in which a single PFC also works sufficiently 
well. There are situations where using multiple additions does improve the curve fit 
versus the single-segment case, but excessive fines still exist. The reason the optimization 
does not add any pure solvent is likely due to the addition of pure solvent causing a 
simultaneous decrease in concentration and decrease in residence time. Both of these 
cause the optimization to take “one step forward and two steps back”, thus adding pure 





CHAPTER 7. SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
7.1 Summary and Conclusions 
The aim of this research was to investigate a new methods of producing pharmaceutical 
drugs using computational methods. The drug industry is undergoing a major shift in the 
way it thinks about manufacturing. Prior batch methods of manufacturing are expensive 
and wasteful, while continuous methods are much more efficient. This motivates the 
study of novel crystallizers. As an example, we have investigated the optimal operation 
and optimal design of a new type of crystallizer, the multi-segment, multi-addition plug 
flow crystallizer, or MSMA-PFC. 
 
The literature review began our work. We started with a general overview of current 
problems in drug manufacture, and new technologies being investigated to address these 
problems. We discussed many of the interesting new technologies being pursued in the 
areas of synthesis, purification, and formulation of pharmaceuticals. 
 
An especially important unit operation is crystallization, from which the vast majority of 




for continuous crystallization are being investigated for application toward 
pharmaceutical purification. 
 
In CHAPTER 4, we discuss one such technology in great detail. This crystallizer uses 
multiple plug-flow elements in series, which allows for finer control of supersaturation in 
one dimension. We have investigated the use of a multi-segment, multi-addition plug 
flow crystallizer (MSMA-PFC) for the production of pharmaceutical API crystals via 
computational methods. We have also shown that the optimization is nonconvex, and is 
not amenable to gradient search methods. Instead, we have utilized the genetic algorithm 
to optimize the decision variables. A multiobjective optimization problem was solved to 
investigate the performance of the crystallizer. The crystallization system was simulated 
by solving the population balance and mass balance equations using, depending on 
circumstance, either the method-of-moments or the finite-volume method. The system is 
run exclusively at steady-state as an antisolvent crystallization. The decision variables 
(among others) are the flowrates of antisolvent (and if applicable, pure solvent) into each 
distinct segment. In this simplified case, we have examined the tradeoff between mass-
mean crystal size and coefficient of variation – though a variety of other objective 
functions could be used to extend the framework further. Our results showed that 
rigorous optimization was able to generate superior designs to what was shown in prior 
literature. Using the Monte-Carlo method, we examined in greater detail the robustness of 
the crystallizer with respect to error in kinetic parameters and antisolvent flowrate. The 
results indicate that there is significant sensitivity to kinetic parameters, though the 




find significant sensitivity with respect to antisolvent flowrate. Error is magnified when 
multiple stages are in error simultaneously. 
 
In CHAPTER 5 We have introduced in this work a new framework for optimizing plug 
flow crystallization systems, which was lacking previously in the literature. Specifically, 
we have developed a combined model and optimization framework for identifying 
optimal designs of the MSMA-PFC. The methodology worked by splitting the MSMA-
PFC into progressively greater numbers of segments, and optimizing mass-mean crystal 
size (or coefficient of variation) over the antisolvent profile. Our first study in this 
chapter used the same total flowrates as in CHAPTER 4 Results show that multiple 
modes in the distribution are observed when maximizing  , but generally a much 
smoother distribution is obtained when minimizing . This behavior persists when feed 
flowrate and total antisolvent are incorporated as decision variables as well. For the 
second part of our study, we permitted total antisolvent flowrate and feed flowrate to be 
decision variables. Under these circumstances, residence time tends to be independent of 
optimization objective. Using the finite volume method, the crystal size distributions 
show multiple modes are present when maximizing , but typically unimodal when 
minimizing . Greatest control (tending toward larger crystal size) was observed when 
using 25 injections, as agrees with intuition. Antisolvent distribution is different when 
maximizing either  or , though in both cases antisolvent sends to be distributed in a 






In CHAPTER 6, we examined the use of the MSMA-PFC for the production crystals 
while dissolving fine crystals in-situ. The results show that the optimization actually does 
not want to dissolve the fine crystals in order to match the CSD. Optimization results 
routinely set pure solvent flow to either zero or small values compared to the feed 
flowrate and total antisolvent flowrate. We have used an orthogonal array experimental 
design to sample the parameter space over the nucleation and growth rate parameters, as 
well as the total crystallizer length. Single-factor analysis of the orthogonal array 
predicted the intuitive result that the best performance would be observed for the case of 
slow nucleation and fast growth. Using the parameters predicted from the single-factor 
analysis, we find that the best results are obtained for smallest values of 89  (low 
nucleation) and highest values of the growth constant, 87. The most sensitive parameter 
is 89, followed by 87. The problem with this situation, is that when compared to using a 
single segment, there is virtually no improvement in performance, e.g. the system was 
already well-behaved to begin with. The best use of in-situ fines dissolution would be for 
the crystallization of low-nucleation systems. For moderate nucleation cases, the MSMA-
PFC results do show improvement over the nucleating case, but still exhibit large 
amounts of fine crystals. At higher levels of nucleation, the systems becomes 
overwhelmed with fines. Examination of the supersaturation profiles reveals that the 
optimization does not make use of dissolution in any of the cases for fines removal. This 
is in contrast to the work by Majumder and Nagy [113] on in-situ fines dissolution using 
a cooling crystallization, which clearly showed the dissolution of fine crystals. The 
reason we believe that antisolvent crystallization fails to make use of dissolution by the 




supersaturation due to the effect of dilution. Furthermore, the addition of pure solvent 
simultaneously decreases the available residence time for crystallization. Thus, the 




7.2 Future Directions 
A variety of extensions of this work are possible. An important next step would be 
experimental verification of the optimal result found in CHAPTER 4 using a lab-scale 
plug flow crystallization system. Another possible direction is robust optimization of the 
flufenamic acid crystallization using a minimax framework. The idea here is to attempt to 
maximize the mean crystal size, but also to simultaneously minimize the mean size by 
manipulating experimental parameters over their uncertainty bounds. The results of this 
study would indicate how robust the crystallization process is to parametric uncertainty. 
Unsteady-state simulation and optimization of the plug flow crystallizer. In this study, 
time-optimal control could be used to optimize a variety of objectives for optimizing the 
startup of the PFC, e.g. minimizing the mass of wasted API. Dynamical analysis of the 
unsteady state MSMA-PFC is another future direction. In this study, variations in 
important parameters could reveal the presence of dynamical anomalies and bifurcations, 
or even chaotic behavior. Residence time effects are also of great importance. Our 
simulations always assumed plug flow, but incorporating a residence time distribution 
model into the framework would allow for better predictive capabilities. Chemical 




begins to crystallize and accumulate on the vessel walls. This interferes with heat transfer, 
and over the long term can reduce residence time by reducing total volume. A strategy is 
needed for the removal of fouling areas once they begin to accumulate, or for a way to 
operate the crystallization such that fouling does not occur. Economic analysis of a plant 
using an MSMA-PFC array is another future direction. A comparison between 
conventional batch technology and MSMPR modes would clearly show which 
technology was more economically viable. Such analysis for the case of MSMPR 
crystallization has already been done by Schaber et al. [5]. In this work, we have 
investigated solely antisolvent crystallization, but it is possible to utilize cooling and 
antisolvent crystallization simultaneously. Instead of a solubility curve, we now have a 
solubility surface with respect to temperature and antisolvent ratio. This allows for a new, 
independent actuator for the control of supersaturation. Polymorphism and chirality are of 
serious concern in drug crystallization. Synthesis of the incorrect solid or optical form 
will, in the best case scenario, lead to an inactive medication. In the worst case scenario, 
the resulting compound will be a deadly toxin. The extension of the framework in this 
work for the optimization of polymorphic form content and of optical form are another 
possible future direction. Significant interaction is known to exist between upstream and 
downstream processes in pharmaceutical manufacture. Another possible future direction 
would be to integrate other unit operations into the crystallization, such as filtration, 
washing, and drying. The final goal would be to optimize the properties of the final dry 
crystals produced at the exit of the crystallization section. Crystal shape is also of great 




population balance. However, two-dimensional population balances are becoming more 
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